{
  "schemaVersion": "deck-intelligence.v1",
  "id": "019de075-d132-769f-97bd-4a840dd24899",
  "slug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "title": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "subtitle": "Aeglea BioTherapeutics · 2023-09",
  "author": "Aeglea BioTherapeutics",
  "date": "2023-09-01 00:00:00",
  "pageCount": 56,
  "kind": "pitchdeck",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "document": {
    "id": "019de075-d132-769f-97bd-4a840dd24899",
    "slug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
    "title": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
    "rawTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
    "authorId": "aeglea-biotherapeutics",
    "authorName": "Aeglea BioTherapeutics",
    "authorDisplay": "Aeglea BioTherapeutics",
    "kind": {
      "slug": "pitchdeck",
      "label": "Pitch deck"
    },
    "sourceType": {
      "slug": "investor_relations",
      "label": "Investor relations"
    },
    "fileName": "2023-09__aeglea-biotherapeutics__investor-pres__9e6f6ffb.pdf",
    "sourceUrl": "https://www.slidebook.io/company/aeglea-biotherapeutics/presentation/9e6f6ffb1a7ecb278276dcbd68bd1d77/",
    "sourceDate": "2023-09-15 00:00:00",
    "presentationDate": "2023-09-01 00:00:00",
    "ingestedAt": "2026-04-30 22:15:10.999615+00",
    "status": "ready",
    "pageCount": 56,
    "orientation": "landscape",
    "aspectRatio": 1.7777778,
    "targetCompany": null,
    "targetTicker": null,
    "metadata": {
      "corpus": "slidebook",
      "industry": "biotechnology",
      "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-09__aeglea-biotherapeutics__investor-pres__9e6f6ffb",
      "image_width": 1920,
      "image_format": "jpg",
      "deck_type_raw": "Investor Presentation Deck",
      "deck_type_slug": null,
      "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/"
    }
  },
  "coverage": {
    "pageCount": 56,
    "pagesIndexed": 56,
    "pagesWithImages": 56,
    "pagesWithMetadata": 56,
    "imageCoveragePct": 100,
    "metadataCoveragePct": 100,
    "componentCount": 274,
    "chartCount": 39,
    "metricSlides": 0,
    "toolMatches": 26,
    "documentToolMatches": 0,
    "frameworkMatches": 33,
    "arcMatches": 1,
    "beatMatches": 4,
    "loopMatches": 3,
    "patternMatches": 0,
    "storymakersMatch": false,
    "scoreAvailable": false,
    "reviewAvailable": false,
    "activistThesisAvailable": false,
    "pitchdeckMetadataAvailable": false,
    "pitchdeckProfileAvailable": false
  },
  "blocks": [],
  "matches": {
    "arcs": [
      {
        "arc": {
          "name": "Problem-Agitate-Solution",
          "slug": "problem-agitate-solution",
          "status": "active",
          "bestFor": "Sales pitches, urgency-driven, competitive displacement",
          "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
          "version": 1,
          "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
          "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
          "description": null,
          "familyLabel": null,
          "categoryName": "Strategy & Business",
          "categorySlug": "strategy-business"
        },
        "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
        "evidence": "The document follows a problem-agitate-solution narrative shape, highlighting the limitations of current biologics, agitating the problem, and presenting Spyre's solution.",
        "isPrimary": true,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-16 22:37:36.099666+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": "doc-narrative-v1"
        }
      }
    ],
    "beats": [
      {
        "to": 8,
        "arc": {
          "name": "Problem-Agitate-Solution",
          "slug": "problem-agitate-solution",
          "status": "active",
          "bestFor": "Sales pitches, urgency-driven, competitive displacement",
          "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
          "version": 1,
          "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
          "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
          "description": null,
          "familyLabel": null,
          "categoryName": "Strategy & Business",
          "categorySlug": "strategy-business"
        },
        "from": 8,
        "name": "Problem (Identify pain)",
        "beatId": "7af050bc-2753-4f31-9805-17415e57f291",
        "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
        "beatType": {
          "name": "Problem (Identify pain)",
          "slug": "problem-agitate-solution-problem-identify-pain",
          "status": "active",
          "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131",
          "version": 1,
          "description": null
        },
        "evidence": "The document identifies the limitations of current biologics and the need for new approaches.",
        "position": 0,
        "isPrimaryArc": true,
        "parentBeatType": {
          "name": "Complication",
          "slug": "complication",
          "status": "active",
          "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579",
          "version": 1,
          "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs."
        },
        "alignedBlockIds": null,
        "matchConfidence": 0.8
      },
      {
        "to": 15,
        "arc": {
          "name": "Problem-Agitate-Solution",
          "slug": "problem-agitate-solution",
          "status": "active",
          "bestFor": "Sales pitches, urgency-driven, competitive displacement",
          "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
          "version": 1,
          "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
          "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
          "description": null,
          "familyLabel": null,
          "categoryName": "Strategy & Business",
          "categorySlug": "strategy-business"
        },
        "from": 8,
        "name": "Agitate (Make it worse)",
        "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
        "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
        "beatType": {
          "name": "Agitate (Make it worse)",
          "slug": "problem-agitate-solution-agitate-make-it-worse",
          "status": "active",
          "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
          "version": 1,
          "description": null
        },
        "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
        "position": 1,
        "isPrimaryArc": true,
        "parentBeatType": {
          "name": "Development",
          "slug": "development",
          "status": "active",
          "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
          "version": 1,
          "description": "The middle stretch in arcs that have one. Often where length problems creep in."
        },
        "alignedBlockIds": null,
        "matchConfidence": 0.8
      },
      {
        "to": 44,
        "arc": {
          "name": "Problem-Agitate-Solution",
          "slug": "problem-agitate-solution",
          "status": "active",
          "bestFor": "Sales pitches, urgency-driven, competitive displacement",
          "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
          "version": 1,
          "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
          "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
          "description": null,
          "familyLabel": null,
          "categoryName": "Strategy & Business",
          "categorySlug": "strategy-business"
        },
        "from": 10,
        "name": "Solution (Provide relief)",
        "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
        "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
        "beatType": {
          "name": "Solution (Provide relief)",
          "slug": "problem-agitate-solution-solution-provide-relief",
          "status": "active",
          "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
          "version": 1,
          "description": null
        },
        "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
        "position": 2,
        "isPrimaryArc": true,
        "parentBeatType": {
          "name": "Resolution",
          "slug": "resolution",
          "status": "active",
          "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
          "version": 1,
          "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
        },
        "alignedBlockIds": null,
        "matchConfidence": 0.8
      },
      {
        "to": 56,
        "arc": {
          "name": "Problem-Agitate-Solution",
          "slug": "problem-agitate-solution",
          "status": "active",
          "bestFor": "Sales pitches, urgency-driven, competitive displacement",
          "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
          "version": 1,
          "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
          "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
          "description": null,
          "familyLabel": null,
          "categoryName": "Strategy & Business",
          "categorySlug": "strategy-business"
        },
        "from": 45,
        "name": "Impact & Next Steps",
        "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
        "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
        "beatType": {
          "name": "Impact & Next Steps",
          "slug": "consultants-gambit-impact-next-steps",
          "status": "active",
          "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
          "version": 1,
          "description": null
        },
        "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
        "position": 3,
        "isPrimaryArc": true,
        "parentBeatType": {
          "name": "Resolution",
          "slug": "resolution",
          "status": "active",
          "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
          "version": 1,
          "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
        },
        "alignedBlockIds": null,
        "matchConfidence": 0.8
      }
    ],
    "loops": [
      {
        "to": 19,
        "from": 10,
        "loop": {
          "name": "03_aha_moment",
          "slug": "03-aha-moment",
          "status": "active",
          "bestFor": "Data-heavy sections, research findings, analytical arguments",
          "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
          "version": 1,
          "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
          "structure": "The Problem/Question -> What the Data Shows -> The Insight",
          "description": "Establish a tension, present data, then deliver the insight that changes everything",
          "familyLabel": null,
          "categoryName": "Narrative",
          "categorySlug": "narrative"
        },
        "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
        "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
        "position": 0,
        "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-16 22:37:36.300053+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": "doc-narrative-v1"
        }
      },
      {
        "to": 11,
        "from": 11,
        "loop": {
          "name": "15_why_now",
          "slug": "15-why-now",
          "status": "active",
          "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
          "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f",
          "version": 1,
          "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
          "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
          "description": "Create temporal urgency by proving that the window of opportunity is opening or closing",
          "familyLabel": null,
          "categoryName": "Urgency",
          "categorySlug": "urgency"
        },
        "matchId": "8e9697fd-79aa-4fe8-a218-0ec6e1bba9da",
        "evidence": "The document highlights the growing market and the need for improved solutions.",
        "position": 1,
        "objective": "Why now is the right time for Spyre's IBD treatment solutions?",
        "confidence": 0.6,
        "extraction": {
          "at": "2026-07-16 22:37:36.341276+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": "doc-narrative-v1"
        }
      },
      {
        "to": 28,
        "from": 28,
        "loop": {
          "name": "47_quick_win_big_bet",
          "slug": "47-quick-win-big-bet",
          "status": "active",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "canonId": "019dd956-790d-708d-983e-ef9bbc68f741",
          "version": 1,
          "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "description": "Separate initiatives into immediate wins and longer-term strategic bets",
          "familyLabel": null,
          "categoryName": "Consulting Framework",
          "categorySlug": "consulting-framework"
        },
        "matchId": "97dc64e0-9ee7-4111-9a96-eee5c2c2a6af",
        "evidence": "The document presents Spyre's plan to rapidly advance combination programs.",
        "position": 2,
        "objective": "What if Spyre's combination programs could create optimal combinations in IBD?",
        "confidence": 0.6,
        "extraction": {
          "at": "2026-07-16 22:37:36.381816+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": "doc-narrative-v1"
        }
      }
    ],
    "tools": [
      {
        "tool": {
          "name": "Table data",
          "slug": "table-data",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
          "version": 1,
          "bodyDocId": null,
          "description": "Tabular layouts of structured data.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "98a90d55-94ed-40a9-999d-0e6366f55b25",
        "evidence": "table/valuation: Shares of common stock outstanding 2.6 million; Pre-funded warrants 1.2 million; Merger consideration: Shares of common 0.5 million, Shares of preferred 0.4 million, Preferred conversion ratio 1:40, Tota",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 00:31:41.030177+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 4,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Market Segmentation Pyramid",
          "slug": "market-segmentation-pyramid",
          "status": "active",
          "bestFor": null,
          "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "16b677f5-5b32-44a4-8621-c253d5f027d3",
        "evidence": "paragraph/paragraph: IBD makes up 22% of the global $100B+ I&I market.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:41.141808+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 6,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Market Segmentation Pyramid",
          "slug": "market-segmentation-pyramid",
          "status": "active",
          "bestFor": null,
          "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "fae4f996-e939-4cdf-9c5b-c2b939c1e0f8",
        "evidence": "paragraph/paragraph: IBD makes up 22% of the global $100B+ I&I market.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:41.216958+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 7,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Problem Statement Canvas",
          "slug": "problem-statement-canvas",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18",
          "version": 1,
          "bodyDocId": null,
          "description": "Structured definition of the problem: What? Who? Where? When? Scale?",
          "familyLabel": null,
          "categoryName": "Block",
          "categorySlug": "block"
        },
        "agent": "Architect",
        "layer": "slide",
        "agents": [
          "Architect"
        ],
        "matchId": "3a56d198-db93-4e92-8c00-954414df13eb",
        "evidence": "title/headline: Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 00:31:41.293083+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 8,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Three Pillars",
          "slug": "three-pillars",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-81ef-7455-a365-b234d95a6bbb",
          "version": 1,
          "bodyDocId": null,
          "description": "Three major supporting arguments that are MECE and address key concerns",
          "familyLabel": null,
          "categoryName": "Block",
          "categorySlug": "block"
        },
        "agent": "Architect",
        "layer": "slide",
        "agents": [
          "Architect"
        ],
        "matchId": "079815c0-bc8b-483e-ab72-674b81c36407",
        "evidence": "list/numbered: 1. Best-in-class mAb engineering (With half-life extension technology) 2. Rational therapeutic combinations 3. Precision patient selection",
        "pageRefs": null,
        "priority": "Core",
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 00:31:41.367816+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 9,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Gantt chart",
          "slug": "gantt-chart",
          "status": "active",
          "bestFor": null,
          "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "ff3482d7-ba69-494a-9742-c9445c816e45",
        "evidence": "chart/gantt-chart: Pipeline development status table",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 00:31:41.592335+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 14,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Audience Definition",
          "slug": "audience-definition",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756",
          "version": 1,
          "bodyDocId": null,
          "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?",
          "familyLabel": null,
          "categoryName": "Block",
          "categorySlug": "block"
        },
        "agent": "Storyteller",
        "layer": "slide",
        "agents": [
          "Storyteller"
        ],
        "matchId": "113a9096-f157-472f-9fbb-473ccd10ed48",
        "evidence": "The slide mentions 'moderate-to-severe UC' and 'preferred biologic', indicating a specific audience.",
        "pageRefs": null,
        "priority": "Core",
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:41.338738+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 16,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "2x2 matrix",
          "slug": "matrix-2x2",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
          "version": 1,
          "bodyDocId": null,
          "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "b0d9bccf-cc50-4be4-a375-5454706ebd32",
        "evidence": "The slide contains a table comparing SPY001 with Entyvio IV and SC across 8 clinical/formulation attributes.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 00:31:41.412049+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 17,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "List presentation",
          "slug": "list-presentation",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1",
          "version": 1,
          "bodyDocId": null,
          "description": "Bulleted, numbered, or checklist enumerations.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "e913d8b8-4c91-41a8-ba6a-1d08fb8822b9",
        "evidence": "The slide uses bullet points to present information about SPY001.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:41.480824+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 18,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Table data",
          "slug": "table-data",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
          "version": 1,
          "bodyDocId": null,
          "description": "Tabular layouts of structured data.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "56ff7ce2-d4d2-49b9-89a0-7db01a7929a6",
        "evidence": "The slide presents a table with EC50 values for Vedolizumab and SPY001.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:41.584655+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 20,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Comparison frame",
          "slug": "comparison-frame",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93",
          "version": 1,
          "bodyDocId": null,
          "description": "Two or more states/subjects placed side by side to expose a gap.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "70ab07c1-f54f-4426-92c3-627abb7108ad",
        "evidence": "table/data: Agent, MOA, Indication, Administration, Efficacy, Safety",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 03:39:02.809521+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 28,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Gantt chart",
          "slug": "gantt-chart",
          "status": "active",
          "bestFor": null,
          "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "6bdc0443-1595-449a-9162-0fcef8d0a33b",
        "evidence": "The slide contains a Gantt chart showing pipeline development status.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 03:39:05.611547+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 30,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "2x2 matrix",
          "slug": "matrix-2x2",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
          "version": 1,
          "bodyDocId": null,
          "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "3886e431-5a42-489d-92a1-70c2da461af5",
        "evidence": "The slide contains a table comparing attributes of multiple drugs.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:05.72538+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 32,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Gantt chart",
          "slug": "gantt-chart",
          "status": "active",
          "bestFor": null,
          "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "d465248c-e35f-4ea4-a5ab-17c96284d01a",
        "evidence": "The slide contains a Gantt chart showing pipeline development status.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 03:39:05.982581+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 38,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Three horizons (McKinsey)",
          "slug": "three-horizons",
          "status": "active",
          "bestFor": null,
          "canonId": "019de52d-1a3c-72cc-b532-f52d3e454a83",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "60b81bcf-619c-40a1-a097-53b6f11c4d25",
        "evidence": "We plan to rapidly advance combination programs in parallel with monotherapies in Phase 2",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:05.599606+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 42,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "2x2 matrix",
          "slug": "matrix-2x2",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
          "version": 1,
          "bodyDocId": null,
          "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "c6e5c85d-d07e-4799-8a01-87b27ee38722",
        "evidence": "Ideal building blocks: Spyre's best-in-class engineered mAbs provide optionality for multiple rational combinations",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:05.680057+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 43,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Venn diagram",
          "slug": "venn-diagram",
          "status": "active",
          "bestFor": null,
          "canonId": "019de52d-1f53-7290-96c8-79388c95fc17",
          "version": 1,
          "bodyDocId": null,
          "description": null,
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "e3b61ccf-1968-4882-9ad6-1419ffba529d",
        "evidence": "Venn diagram of IL-23, TL1A, and alpha4beta7 targets",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 03:39:05.759463+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 44,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Chart Selection Guide",
          "slug": "chart-selection-guide",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae",
          "version": 1,
          "bodyDocId": null,
          "description": "Choosing the right chart type for your data and message",
          "familyLabel": null,
          "categoryName": "Slide",
          "categorySlug": "slide"
        },
        "agent": "Designer",
        "layer": "slide",
        "agents": [
          "Designer"
        ],
        "matchId": "21303186-6208-4e9f-ac42-832bdb6b2992",
        "evidence": "chart/bar-grouped: Prometheus Biosciences PRA023 TL1A clinical remission at 12 weeks",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:05.839384+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 45,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Section divider",
          "slug": "section-divider",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7",
          "version": 1,
          "bodyDocId": null,
          "description": "A transitional slide marking the start of a new section.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "3fdd597b-2fd5-401e-b8e5-8ef5dcfa5076",
        "evidence": "Corporate",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-07-17 03:39:05.921554+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 46,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Table data",
          "slug": "table-data",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
          "version": 1,
          "bodyDocId": null,
          "description": "Tabular layouts of structured data.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "4d3ad0d8-1f90-4f7a-80f0-21d702b51bb9",
        "evidence": "Table comparing Prometheus, Morphic, Dice, Ventyx, Pliant, and Spyre across IPO raise, market cap, clinical stage, and program status.",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:06.085746+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 49,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Table data",
          "slug": "table-data",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
          "version": 1,
          "bodyDocId": null,
          "description": "Tabular layouts of structured data.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "53980d8d-7a79-4d1f-a817-6be83f6bdbe1",
        "evidence": "table/data: Acquirer, Target, Deal economics, Status, Spyre timeline",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 03:39:06.165645+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 50,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Storytelling: the closing ask",
          "slug": "closing-ask",
          "status": "active",
          "bestFor": null,
          "canonId": "019df269-24e0-70ab-8dd9-983832c1c665",
          "version": 1,
          "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d",
          "description": "The single most important slide in the deck — after the cover. The final",
          "familyLabel": "narrative-block",
          "categoryName": "Narrative & Transformation",
          "categorySlug": "narrative-transformation"
        },
        "agent": "storyteller",
        "layer": "slide",
        "agents": [
          "storyteller"
        ],
        "matchId": "b0756db2-7914-450b-83b3-e36e3e06e7c4",
        "evidence": "Thank you",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-07-17 03:39:06.246653+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 51,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "List presentation",
          "slug": "list-presentation",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1",
          "version": 1,
          "bodyDocId": null,
          "description": "Bulleted, numbered, or checklist enumerations.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "39871475-b15f-4f64-accc-efc99bc20edc",
        "evidence": "list/bullet: Cross-species immunization, Hybridoma approaches, Single B-cell cloning, Phage display, Yeast display, In-silico design",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-07-17 00:31:50.268198+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 53,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "2x2 matrix",
          "slug": "matrix-2x2",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
          "version": 1,
          "bodyDocId": null,
          "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
          "familyLabel": null,
          "categoryName": null,
          "categorySlug": null
        },
        "agent": null,
        "layer": "slide",
        "agents": null,
        "matchId": "210e15bc-7c58-4967-b2b4-3521e5fb8f10",
        "evidence": "framework/instance: Five-pillar optimization framework",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.5,
        "extraction": {
          "at": "2026-07-17 00:31:50.343277+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 54,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": "common",
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Before-After-Bridge",
          "slug": "before-after-bridge",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-8604-7188-883f-42370288ad05",
          "version": 1,
          "bodyDocId": null,
          "description": "Narrative structure: Paint the before, show the after, explain the bridge",
          "familyLabel": null,
          "categoryName": "Block",
          "categorySlug": "block"
        },
        "agent": "Storyteller",
        "layer": "slide",
        "agents": [
          "Storyteller"
        ],
        "matchId": "ad59d031-a01e-4d24-b04f-e7b9543b9617",
        "evidence": "diagram/process: Comparison of 1st gen mAb vs Spyre mAb recycling pathways via FcRn",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-07-17 00:31:50.417956+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 55,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      },
      {
        "tool": {
          "name": "Chart Selection Guide",
          "slug": "chart-selection-guide",
          "status": "active",
          "bestFor": null,
          "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae",
          "version": 1,
          "bodyDocId": null,
          "description": "Choosing the right chart type for your data and message",
          "familyLabel": null,
          "categoryName": "Slide",
          "categorySlug": "slide"
        },
        "agent": "Designer",
        "layer": "slide",
        "agents": [
          "Designer"
        ],
        "matchId": "b585621c-2456-4f5b-8a0f-e9ddb9086eb0",
        "evidence": "chart/scatter: YTE mAbs have extended half-lives in NHPs and humans chart/bar-grouped: ADA rates are similar for YTE and non-YTE antibodies",
        "pageRefs": null,
        "priority": null,
        "whenToUse": null,
        "confidence": 0.6,
        "extraction": {
          "at": "2026-07-17 00:31:50.492834+00",
          "model": "or:meta-llama/llama-4-scout",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 56,
        "whyItWorks": null,
        "antipattern": null,
        "cardinality": null,
        "narrativePurpose": null
      }
    ],
    "frameworks": [
      {
        "matchId": "40dd7322-a30a-4eec-a745-c86b8b0b9e0a",
        "evidence": "Pipeline development timeline visualization",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:31.292+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 5,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "3fb6141c-d5a6-4c16-8293-95bb7d8765d7",
        "evidence": "Compares current standard of care against a future target state on a 2D axis.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:33.108+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 8,
        "frameworkName": "comparison-frame"
      },
      {
        "matchId": "8ae7a5c2-aabb-477d-bd18-a3e3cbfdc527",
        "evidence": "Numbered list of strategic pillars",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:31.837+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 9,
        "frameworkName": "list-presentation"
      },
      {
        "matchId": "de386abd-5724-49f2-805c-518eaad92547",
        "evidence": "Clinical Precedent chart",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:32.814+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 10,
        "frameworkName": "authority-citation"
      },
      {
        "matchId": "2bc7f346-9db5-46d1-b6fe-8b7c38b79373",
        "evidence": "Cites Lancet Gastroenterol. Hepatol. study to validate the therapeutic strategy.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:33.633+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 11,
        "frameworkName": "authority-citation"
      },
      {
        "matchId": "65fe2303-8515-47a5-882c-d650c3a276ca",
        "evidence": "Uses clinical precedent data to validate the efficacy of the proposed diagnostic approach.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:32.552+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 12,
        "frameworkName": "authority-citation"
      },
      {
        "matchId": "029d79b3-a888-49dd-bf84-cdf6a3cc42d0",
        "evidence": "Pipeline development stages visualized over time/status",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:33.083+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 13,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "4122e329-c419-43f2-ae15-2bc348c3790f",
        "evidence": "Pipeline development stages mapped against programs over time",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:32.199+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 14,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "6c76bd93-aa70-4007-a1cb-35b2bce10d6f",
        "evidence": "The slide compares efficacy and safety across multiple drug classes.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:42.252+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 16,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "47336e5d-7790-41be-b174-989f3c4ee008",
        "evidence": "Direct feature-by-feature comparison against competitors",
        "framework": null,
        "confidence": 1,
        "extraction": {
          "at": "2026-05-02 11:32:32.497+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 17,
        "frameworkName": "comparison-frame"
      },
      {
        "matchId": "fe42138c-85ee-48e2-a0e9-97d117b0469e",
        "evidence": "Direct visual comparison of two products across dosing and comfort metrics.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:33.59+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 23,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "39ec9092-b053-4a31-ab77-36ade4a23238",
        "evidence": "Comparing benchmark MOA data against specific drug exposure quartiles to identify a market opportunity.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:34.332+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 24,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "b2212ef8-30cc-4dcc-8622-3dbf86cc7012",
        "evidence": "The program summary is organized into a 2x2 grid of key value propositions.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:34.844+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 26,
        "frameworkName": "matrix-2x2"
      },
      {
        "matchId": "5fd75906-0f10-4bbe-8138-c2d77af66ec1",
        "evidence": "Comparison of market cap at clinical milestones",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:34.444+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 27,
        "frameworkName": "peer_benchmark"
      },
      {
        "matchId": "7ffa6f07-a313-4593-af65-f998d0e2e720",
        "evidence": "The slide uses a structured table to compare the subject product against two direct competitors.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:34.405+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 28,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "2af25032-38e6-4757-9dbf-5cfa37c60668",
        "evidence": "Using KOL quotes to validate market preference",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:34.446+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 29,
        "frameworkName": "authority-citation"
      },
      {
        "matchId": "258b2ac4-f3fe-45b6-bbde-528e89482f9d",
        "evidence": "Pipeline visualization showing stages of development over time",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:37.106+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 30,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "de734179-f3c0-4f1a-9cf1-3da9ea5f74c3",
        "evidence": "The slide presents a structured grid comparing product attributes across multiple competitors.",
        "framework": null,
        "confidence": 1,
        "extraction": {
          "at": "2026-05-02 11:32:35.208+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 32,
        "frameworkName": "comparison_table"
      },
      {
        "matchId": "77c77703-0f83-440c-b1d1-156a07a8bb12",
        "evidence": "Comparing two different therapeutic approaches (monomeric/trimeric vs trimeric-only) to justify a dual-track strategy.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:38.808+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 34,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "88aa400c-e5dc-4cf5-a049-966112b1a699",
        "evidence": "The program summary is organized into a 2x2 grid of key value propositions.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:35.858+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 36,
        "frameworkName": "matrix-2x2"
      },
      {
        "matchId": "66f35c30-ae38-4553-8f4b-a2ac92bf316a",
        "evidence": "Sequential progression of indications shown as rising peaks",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:37.4+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 37,
        "frameworkName": "roadmap"
      },
      {
        "matchId": "0cfad16c-3b5c-43e4-bf21-00c700e4a09a",
        "evidence": "Visual representation of project timelines and stages",
        "framework": null,
        "confidence": 1,
        "extraction": {
          "at": "2026-05-02 11:32:35.661+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 38,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "5f6d4669-5ccc-4861-a108-d4868f8f0645",
        "evidence": "Comparing single agents vs combination therapy efficacy",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:37.105+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 40,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "1125a9ae-76a4-46cc-b622-acbd6419b761",
        "evidence": "Table comparing programs across efficacy, safety, and dosing metrics.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:36.579+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 41,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "a845d93c-4636-4067-b07e-eeb8f07c9ced",
        "evidence": "The slide uses a timeline-based process flow to represent clinical trial phases.",
        "framework": null,
        "confidence": 0.7,
        "extraction": {
          "at": "2026-05-02 11:32:36.847+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 42,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "60c41f30-ded0-4f7b-a96a-b1be3fd2fa6e",
        "evidence": "JNJ VEGA study cited as precedent",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:36.562+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 43,
        "frameworkName": "authority-citation"
      },
      {
        "matchId": "9146835f-1935-4594-b994-d284da26b00a",
        "evidence": "Diagnostic-led therapeutic selection",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:36.812+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 44,
        "frameworkName": "precision-medicine-framework"
      },
      {
        "matchId": "1602fe44-ab6b-4f43-ad39-9ec1cfdc5889",
        "evidence": "Side-by-side comparison of two clinical trial results to prove a hypothesis.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:36.901+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 45,
        "frameworkName": "comparison-frame"
      },
      {
        "matchId": "4ff8b655-97ad-4bbd-88f3-c02fff3cf7de",
        "evidence": "The slide maps specific project milestones against a chronological timeline (2023-2025).",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:36.562+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 48,
        "frameworkName": "gantt-chart"
      },
      {
        "matchId": "f1f8b13a-924e-48e2-812e-ac3a52d0c0e1",
        "evidence": "Compares peer company performance metrics against internal projections.",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:40.465+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 49,
        "frameworkName": "comparison-frame"
      },
      {
        "matchId": "ef682ad4-ffe5-4c41-bae0-ab5f6d49d0ac",
        "evidence": "Table comparing external M&A benchmarks to internal pipeline milestones",
        "framework": null,
        "confidence": 0.9,
        "extraction": {
          "at": "2026-05-02 11:32:36.562+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 50,
        "frameworkName": "comparison_frame"
      },
      {
        "matchId": "9bcf1a98-ab22-448c-9963-864f73bc4a51",
        "evidence": "Visual pentagon structure used to categorize five distinct engineering properties.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:38.698+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 54,
        "frameworkName": "pentagon-optimization-model"
      },
      {
        "matchId": "60cfd52e-2ba2-4706-a3d0-78bcb57af41b",
        "evidence": "The diagram illustrates the biological process of antibody recycling.",
        "framework": null,
        "confidence": 0.8,
        "extraction": {
          "at": "2026-05-02 11:32:38.37+00",
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "seconds": null,
          "promptVersion": null
        },
        "pageNumber": 55,
        "frameworkName": "process"
      }
    ],
    "patterns": []
  },
  "storymakers": null,
  "score": null,
  "review": null,
  "activistThesis": null,
  "pitchdeck": {
    "metadata": null,
    "profile": null
  },
  "slides": [
    {
      "page": 1,
      "type": "setup",
      "title": "The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.",
      "function": "front_matter",
      "imagePath": "https://imgproxy.kitesheet.com/fP2olevAOiGWuUVMRCp3PoNbSJbJ1aD8XjWdfm_EIas/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLmpwZw",
      "rawType": "cover",
      "block": null,
      "metadata": {
        "slideType": "cover",
        "slideTypeCanon": {
          "name": "Cover",
          "slug": "cover",
          "status": "active",
          "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410",
          "version": 1,
          "description": null
        },
        "function": "front_matter",
        "functionCanon": {
          "name": "Front matter",
          "slug": "front_matter",
          "status": "active",
          "canonId": "019de52d-133d-73f0-9e26-201eda96b098",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 19,
        "componentCount": 4,
        "textChars": 66,
        "nDataPoints": 0,
        "notes": "The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:30.948+00",
          "seconds": 2.434,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/1",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-1",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.2,
            "w": 0.25,
            "x": 0.05,
            "y": 0.3
          },
          "kind": "image",
          "text": "Spyre Therapeutics logo",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:30.948+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6fd287ac-aac3-4e06-9c7d-fe2742c3a491",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.25,
            "x": 0.05,
            "y": 0.15
          },
          "kind": "image",
          "text": "Aeglea logo",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:30.948+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9437ca7f-d0f3-4072-aa64-364482cd8979",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.2,
            "x": 0.4,
            "y": 0.6
          },
          "kind": "paragraph",
          "text": "September 2023",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:30.948+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4ae3928a-64d8-4148-ac48-fcb55a5bb28d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.5,
            "x": 0.4,
            "y": 0.5
          },
          "kind": "title",
          "text": "CORPORATE OVERVIEW",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:30.948+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "95b7294e-7025-4973-bd38-134a26d080a0",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "thumbSrc": "https://imgproxy.kitesheet.com/71_PhsMWZPClbkArUuf2AjuMEdP5jJmQnoeL1FfcG6c/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLmpwZw",
      "imagePathAlt": "https://imgproxy.kitesheet.com/HB4acLJv_1BiYcX91ggomBM30UwTP6A_iC2iW1GcPHs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLnBuZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/o-WpA0ta3n_vTu5N7a9ACi5GzpT_1_eFjW8r2iTBZS4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ZTZmNmZmYjFhN2VjYjI3ODI3NmRjYmQ2OGJkMWQ3Ny9wMDAxLnBuZw"
    },
    {
      "page": 2,
      "type": "setup",
      "function": "other",
      "rawType": "appendix_disclosure",
      "block": null,
      "metadata": {
        "slideType": "appendix_disclosure",
        "slideTypeCanon": {
          "name": "Appendix disclosure",
          "slug": "appendix_disclosure",
          "status": "active",
          "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616",
          "version": 1,
          "description": null
        },
        "function": "other",
        "functionCanon": {
          "name": "Other (fallback)",
          "slug": "other",
          "status": "active",
          "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 17,
        "componentCount": 3,
        "textChars": 166,
        "nDataPoints": 0,
        "notes": null,
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:31.19+00",
          "seconds": 2.506,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/2",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-2",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.75,
            "w": 0.95,
            "x": 0.025,
            "y": 0.14
          },
          "kind": "disclaimer",
          "text": "The information contained in this presentation has been prepared by Aeglea Biotherapeutics, Inc. and its affiliates, including Spyre Therapeutics, Inc. ...",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.19+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "10b6a856-ab38-4f04-b23e-7e2f08390cf9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.07,
            "w": 0.06,
            "x": 0.91,
            "y": 0.03
          },
          "kind": "image",
          "text": null,
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.19+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "06e81cc4-0f8b-4863-8993-0c4ada964887",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.06,
            "w": 0.18,
            "x": 0.025,
            "y": 0.035
          },
          "kind": "title",
          "text": "Disclosures",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.19+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7f2e40e4-76ac-45c6-8f7b-23db864848c4",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 3,
      "type": "appendix",
      "function": "summarize",
      "rawType": "other",
      "block": null,
      "metadata": {
        "slideType": "other",
        "slideTypeCanon": {
          "name": "Other (fallback)",
          "slug": "other",
          "status": "active",
          "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43",
          "version": 1,
          "description": null
        },
        "function": "summarize",
        "functionCanon": {
          "name": "Summarize",
          "slug": "summarize",
          "status": "active",
          "canonId": "019de52d-1541-704f-b86f-bf7b75056373",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 65,
        "componentCount": 5,
        "textChars": 957,
        "nDataPoints": 1,
        "notes": null,
        "elementsJson": null,
        "confidence": 0.95,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:31.806+00",
          "seconds": 2.884,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/3",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-3",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.248,
            "w": 0.466,
            "x": 0.274,
            "y": 0.148
          },
          "kind": "image",
          "text": null,
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.806+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "12986550-ba6d-4c98-aaf1-8aae18f96274",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.115,
            "w": 0.948,
            "x": 0.026,
            "y": 0.418
          },
          "kind": "paragraph",
          "text": "Financing: Concurrent with the acquisition of Spyre, Aeglea closed a $210 million private placement with a group of institutional accredited investors led by Fairmount Funds and joined by a robust syndicate of dedicated biotechnology investors as well as additional undisclosed institutional investors.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.806+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "119ea56d-b6fa-45dc-8362-35d8bcb9c945",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.115,
            "w": 0.948,
            "x": 0.026,
            "y": 0.552
          },
          "kind": "paragraph",
          "text": "Primary use of proceeds: The proceeds from the private placement are expected to be primarily used to advance the Spyre pipeline and deliver the following anticipated milestones: two INDs for SPY001 and SPY002 in 2024, HV PK/PD data for SPY001 in 2H2024, and HV PK/PD data for SPY002 in 1H2025. Proceeds are expected to provide cash runway into 2026.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.806+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4182a9e5-68a4-4b2b-b9e1-84b84995c036",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.115,
            "w": 0.948,
            "x": 0.026,
            "y": 0.284
          },
          "kind": "paragraph",
          "text": "Structure: The acquisition of Spyre was structured as a stock-for-stock transaction whereby all of Spyre’s outstanding equity interests were exchanged for a combination of shares of Aeglea common stock and a newly created non-voting Series A convertible preferred stock.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.806+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7e7be8fc-af7e-4b10-acfc-f06b59896119",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.045,
            "w": 0.435,
            "x": 0.026,
            "y": 0.038
          },
          "kind": "title",
          "text": "Aeglea-Spyre Transaction highlights",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.806+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "20c629f6-1c76-4d1f-b3c7-ed69c17034d6",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 4,
      "type": "analysis",
      "title": "Includes a footnote regarding a 1-for-25 reverse stock split.",
      "function": "analyze_data",
      "rawType": "appendix_data",
      "block": null,
      "metadata": {
        "slideType": "appendix_data",
        "slideTypeCanon": {
          "name": "Appendix data",
          "slug": "appendix_data",
          "status": "active",
          "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd",
          "version": 1,
          "description": null
        },
        "function": "analyze_data",
        "functionCanon": {
          "name": "Analyze data",
          "slug": "analyze_data",
          "status": "active",
          "canonId": "019de52d-1590-7413-8c82-cc218cff40b4",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 76,
        "componentCount": 6,
        "textChars": 955,
        "nDataPoints": 9,
        "notes": "Includes a footnote regarding a 1-for-25 reverse stock split.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:31.799+00",
          "seconds": 2.821,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/4",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-4",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.05,
            "w": 0.4,
            "x": 0.58,
            "y": 0.63
          },
          "kind": "disclaimer",
          "text": "Please refer to the company’s SEC filings for additional information.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e3989309-6f40-48cb-956d-bfdd1c626dc9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.35,
            "w": 0.4,
            "x": 0.58,
            "y": 0.15
          },
          "kind": "list",
          "text": "Shares of common stock and preferred stock were issued to Spyre security holders in exchange for all of Spyre’s outstanding equity interests. Shares of preferred stock were issued to Spyre stockholders and to investors in the $210 million private placement.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "aa0b339b-9c8c-4441-9706-75b6b39050f6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.4,
            "x": 0.58,
            "y": 0.47
          },
          "kind": "paragraph",
          "text": "Each share of preferred stock will automatically convert into 40 shares of common stock upon stockholder approval, subject to certain beneficial ownership restrictions set by each holder.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e2b9dd65-92b0-4f29-be7c-23be7e872dc0",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.85,
            "x": 0.026,
            "y": 0.9
          },
          "kind": "source-note",
          "text": "Note: All figures have been retroactively adjusted to reflect the company's 1-for-25 reverse stock split that will be effective as of 12:01 a.m. Eastern Time on September 8, 2023.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b84dccb8-071e-4a27-a196-b7f9d58427e6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.65,
            "w": 0.49,
            "x": 0.026,
            "y": 0.15
          },
          "kind": "table",
          "text": "Shares of common stock outstanding 2.6 million; Pre-funded warrants 1.2 million; Merger consideration: Shares of common 0.5 million, Shares of preferred 0.4 million, Preferred conversion ratio 1:40, Total pre-financing common equivalent 18.9 million",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Valuation table",
              "slug": "valuation",
              "status": "active",
              "canonId": "019de52d-034c-74ed-b5c8-22b5e6ac196d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "valuation",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "98b9114d-bc7b-4fe6-9a6f-38088259e7f6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.23,
            "x": 0.026,
            "y": 0.038
          },
          "kind": "title",
          "text": "Capitalization",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.799+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7c63d77c-7f70-4d24-811b-9c17f0a59b9b",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Table data",
            "slug": "table-data",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
            "version": 1,
            "bodyDocId": null,
            "description": "Tabular layouts of structured data.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "98a90d55-94ed-40a9-999d-0e6366f55b25",
          "evidence": "table/valuation: Shares of common stock outstanding 2.6 million; Pre-funded warrants 1.2 million; Merger consideration: Shares of common 0.5 million, Shares of preferred 0.4 million, Preferred conversion ratio 1:40, Tota",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 00:31:41.030177+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 4,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 5,
      "type": "resolution",
      "title": "The slide uses a pipeline chart format to show the development status of seven different programs.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 35,
        "componentCount": 4,
        "textChars": 227,
        "nDataPoints": 2,
        "notes": "The slide uses a pipeline chart format to show the development status of seven different programs.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:31.292+00",
          "seconds": 2.288,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/5",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-5",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.12,
            "w": 0.23,
            "x": 0.04,
            "y": 0.155
          },
          "kind": "image",
          "text": "Spyre Therapeutics",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.292+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e356fc8d-d8cf-4c69-a6e1-3ff7b677a2bc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.55,
            "w": 0.28,
            "x": 0.04,
            "y": 0.33
          },
          "kind": "list",
          "text": "Opportunity for best-in-class Long-acting antibodies; Rational therapeutic combinations; Precision patient selection",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.292+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ed94d499-5922-40ae-8ebc-e01159e0f3dd",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.7,
            "w": 0.65,
            "x": 0.32,
            "y": 0.18
          },
          "kind": "table",
          "text": "Parallel lead programs against high value targets",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.292+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "11941b8a-f074-4a97-bdd0-6aa7d87e1fcc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.45,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre aims to transform the treatment of IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.292+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4abad2e6-104f-4857-8c56-0f23007e7218",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "40dd7322-a30a-4eec-a745-c86b8b0b9e0a",
          "evidence": "Pipeline development timeline visualization",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:31.292+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 5,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 6,
      "type": "resolution",
      "function": "size_opportunity",
      "rawType": "market_sizing",
      "block": null,
      "metadata": {
        "slideType": "market_sizing",
        "slideTypeCanon": {
          "name": "Market sizing",
          "slug": "market_sizing",
          "status": "active",
          "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b",
          "version": 1,
          "description": null
        },
        "function": "size_opportunity",
        "functionCanon": {
          "name": "Size opportunity",
          "slug": "size_opportunity",
          "status": "active",
          "canonId": "019de52d-147b-7568-8828-a74a27697618",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 77,
        "componentCount": 8,
        "textChars": 503,
        "nDataPoints": 5,
        "notes": null,
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.873+00",
          "seconds": 3.842,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/6",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-6",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.5,
            "x": 0.45,
            "y": 0.75
          },
          "kind": "callout",
          "text": "IBD represents a multi-billion dollar market opportunity for best-in-class biologics.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e8bd1eea-6354-437b-8eb8-20860aff3ecc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.5,
            "x": 0.45,
            "y": 0.25
          },
          "kind": "chart",
          "text": "2021 Global IBD Market",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "593897d2-f1cd-4e8a-9333-71a842694577",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.15,
            "x": 0.25,
            "y": 0.65
          },
          "kind": "metric",
          "text": "$29B+ estimated IBD market globally in 2028.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "966b5e2d-ed05-4ae4-ad17-ee7013bfdf7c",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.05,
            "y": 0.3
          },
          "kind": "metric",
          "text": "~1.7M IBD patients diagnosed in the US.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b2bd0dc5-9f78-4a88-bd42-68ec31d3406a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.05,
            "y": 0.6
          },
          "kind": "paragraph",
          "text": "Biologics are the preferred modality for moderate-to-severe patients due to superior benefit-risk profile.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0182842a-1cdb-4c6d-a207-e83a16b87cb8",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.15,
            "x": 0.25,
            "y": 0.35
          },
          "kind": "paragraph",
          "text": "IBD makes up 22% of the global $100B+ I&I market.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "97db5217-7d3e-45f7-9659-65290a2ba576",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.3,
            "x": 0.05,
            "y": 0.9
          },
          "kind": "source-note",
          "text": "Sources: Global Data, Evaluate Pharma, UpToDate, SVB Leerink.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "bcb4cd40-3271-4fd1-93de-a2e653116bb3",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "Inflammatory bowel disease is a growing $21B market in which biologics are the preferred modality",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4a8a0902-9d32-48dd-8f84-df7c37c88034",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Market Segmentation Pyramid",
            "slug": "market-segmentation-pyramid",
            "status": "active",
            "bestFor": null,
            "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "16b677f5-5b32-44a4-8621-c253d5f027d3",
          "evidence": "paragraph/paragraph: IBD makes up 22% of the global $100B+ I&I market.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:41.141808+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 6,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 7,
      "type": "resolution",
      "title": "The slide uses a donut chart to illustrate market growth from 2021 to 2028.",
      "function": "size_opportunity",
      "rawType": "market_sizing",
      "block": null,
      "metadata": {
        "slideType": "market_sizing",
        "slideTypeCanon": {
          "name": "Market sizing",
          "slug": "market_sizing",
          "status": "active",
          "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b",
          "version": 1,
          "description": null
        },
        "function": "size_opportunity",
        "functionCanon": {
          "name": "Size opportunity",
          "slug": "size_opportunity",
          "status": "active",
          "canonId": "019de52d-147b-7568-8828-a74a27697618",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 77,
        "componentCount": 8,
        "textChars": 503,
        "nDataPoints": 4,
        "notes": "The slide uses a donut chart to illustrate market growth from 2021 to 2028.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.876+00",
          "seconds": 3.755,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/7",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-7",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.45,
            "x": 0.45,
            "y": 0.75
          },
          "kind": "callout",
          "text": "IBD represents a multi-billion dollar market opportunity for best-in-class biologics.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c35cf3c4-f22c-4d01-89fe-38084adb6d44",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.45,
            "x": 0.45,
            "y": 0.25
          },
          "kind": "chart",
          "text": "2021 Global IBD Market",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4c77da64-6bb8-4526-aa95-6ebf328e3040",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.15,
            "x": 0.05,
            "y": 0.3
          },
          "kind": "metric",
          "text": "~1.7M IBD patients diagnosed in the US.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "358c979f-3fe5-4b4e-bbd6-9ac7f3c6a31f",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.15,
            "x": 0.25,
            "y": 0.6
          },
          "kind": "metric",
          "text": "$29B+ estimated IBD market globally in 2028.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f8b0ff3e-7e1b-473e-887c-423a84b250ae",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.15,
            "x": 0.25,
            "y": 0.3
          },
          "kind": "paragraph",
          "text": "IBD makes up 22% of the global $100B+ I&I market.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "2a155225-ac76-46d8-a8cb-851494ac5b96",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.05,
            "y": 0.6
          },
          "kind": "paragraph",
          "text": "Biologics are the preferred modality for moderate-to-severe patients due to superior benefit-risk profile.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7e47431c-201d-4944-84e3-10d4e3ab8ff8",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.3,
            "x": 0.05,
            "y": 0.9
          },
          "kind": "source-note",
          "text": "Sources: Global Data, Evaluate Pharma, UpToDate, SVB Leerink.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "eb637b6d-558a-4a9d-b69e-ea05add38943",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "Inflammatory bowel disease is a growing $21B market in which biologics are the preferred modality",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.876+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d8ae167b-0024-41c1-b544-f2449e278783",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Market Segmentation Pyramid",
            "slug": "market-segmentation-pyramid",
            "status": "active",
            "bestFor": null,
            "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "fae4f996-e939-4cdf-9c5b-c2b939c1e0f8",
          "evidence": "paragraph/paragraph: IBD makes up 22% of the global $100B+ I&I market.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:41.216958+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 7,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [],
      "loops": [],
      "locked": true
    },
    {
      "page": 8,
      "type": "tension",
      "title": "The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.",
      "function": "frame_problem",
      "rawType": "problem_statement",
      "block": null,
      "metadata": {
        "slideType": "problem_statement",
        "slideTypeCanon": {
          "name": "Problem statement",
          "slug": "problem_statement",
          "status": "active",
          "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4",
          "version": 1,
          "description": null
        },
        "function": "frame_problem",
        "functionCanon": {
          "name": "Frame problem",
          "slug": "frame_problem",
          "status": "active",
          "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 63,
        "componentCount": 5,
        "textChars": 614,
        "nDataPoints": 8,
        "notes": "The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.108+00",
          "seconds": 3.549,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/8",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-8",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.2,
            "x": 0.22,
            "y": 0.5
          },
          "kind": "callout",
          "text": "SOC today",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9c00bf9b-3051-411f-9c3a-03b359a9ac9c",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.15,
            "x": 0.6,
            "y": 0.25
          },
          "kind": "callout",
          "text": "Spyre target",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e10288eb-d01d-479a-9e22-77ee4838b8ca",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.85,
            "x": 0.07,
            "y": 0.245
          },
          "kind": "chart",
          "text": "UC Maintenance Remission Rates vs Maintenance dosing frequency",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Scatter plot",
              "slug": "scatter",
              "status": "active",
              "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "scatter",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7466b6c3-6a00-4150-865b-2a1cbc046f7d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.95,
            "x": 0.02,
            "y": 0.86
          },
          "kind": "source-note",
          "text": "Summary data for select agents that randomize patients post response to induction; data from labels, company reports. Vedolizumab approved in US as Q8W IV – Q2W SC approval pending following CRL in 2019. TL1A maintenance data not available. Orals not shown (pbo-adj maintenance remission rates): Jaks - tofacitinib (27%), upadacitinib (30% 15mg, 40% 30mg); S1Ps: ozanimod (19%); etrasimod (25% - P3 Treat-through design).",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "987a76d4-3038-4db6-a144-c698a687b9af",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.88,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3aa77f99-1c2d-4044-9a64-612a78f17ffa",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Problem Statement Canvas",
            "slug": "problem-statement-canvas",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18",
            "version": 1,
            "bodyDocId": null,
            "description": "Structured definition of the problem: What? Who? Where? When? Scale?",
            "familyLabel": null,
            "categoryName": "Block",
            "categorySlug": "block"
          },
          "agent": "Architect",
          "layer": "slide",
          "agents": [
            "Architect"
          ],
          "matchId": "3a56d198-db93-4e92-8c00-954414df13eb",
          "evidence": "title/headline: Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 00:31:41.293083+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 8,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "3fb6141c-d5a6-4c16-8293-95bb7d8765d7",
          "evidence": "Compares current standard of care against a future target state on a 2D axis.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:33.108+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 8,
          "frameworkName": "comparison-frame"
        }
      ],
      "arcBeats": [
        {
          "to": 8,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Problem (Identify pain)",
          "beatId": "7af050bc-2753-4f31-9805-17415e57f291",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Problem (Identify pain)",
            "slug": "problem-agitate-solution-problem-identify-pain",
            "status": "active",
            "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131",
            "version": 1,
            "description": null
          },
          "evidence": "The document identifies the limitations of current biologics and the need for new approaches.",
          "position": 0,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Complication",
            "slug": "complication",
            "status": "active",
            "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579",
            "version": 1,
            "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 9,
      "type": "setup",
      "title": "The slide uses a numbered list format to present strategic pillars.",
      "function": "present_framework",
      "rawType": "key_messages",
      "block": null,
      "metadata": {
        "slideType": "key_messages",
        "slideTypeCanon": {
          "name": "Key messages",
          "slug": "key_messages",
          "status": "active",
          "canonId": "019de52d-0712-703f-89f5-bda6688faf3f",
          "version": 1,
          "description": null
        },
        "function": "present_framework",
        "functionCanon": {
          "name": "Present framework",
          "slug": "present_framework",
          "status": "active",
          "canonId": "019de52d-1403-7667-9100-d2ac6709f750",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 23,
        "componentCount": 3,
        "textChars": 257,
        "nDataPoints": 0,
        "notes": "The slide uses a numbered list format to present strategic pillars.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:31.837+00",
          "seconds": 2.231,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/9",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-9",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.5,
            "w": 0.86,
            "x": 0.07,
            "y": 0.35
          },
          "kind": "list",
          "text": "1. Best-in-class mAb engineering (With half-life extension technology) 2. Rational therapeutic combinations 3. Precision patient selection",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Numbered list",
              "slug": "numbered",
              "status": "active",
              "canonId": "019de52c-fcc0-7718-a284-a4250c805df2",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "numbered",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.837+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e2cc370f-4f51-4aa7-b584-e2fa47f6fb29",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.58,
            "x": 0.21,
            "y": 0.24
          },
          "kind": "title",
          "text": "Three strategic pillars in an effort to create the preeminent IBD company",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.837+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "45471586-9299-4d5b-aeb0-1b8d53e3bb7a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.06,
            "w": 0.45,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre's strategy to address unmet needs in IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:31.837+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8a7ee25b-a026-4f37-9bfa-2d23bdc362d8",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Three Pillars",
            "slug": "three-pillars",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-81ef-7455-a365-b234d95a6bbb",
            "version": 1,
            "bodyDocId": null,
            "description": "Three major supporting arguments that are MECE and address key concerns",
            "familyLabel": null,
            "categoryName": "Block",
            "categorySlug": "block"
          },
          "agent": "Architect",
          "layer": "slide",
          "agents": [
            "Architect"
          ],
          "matchId": "079815c0-bc8b-483e-ab72-674b81c36407",
          "evidence": "list/numbered: 1. Best-in-class mAb engineering (With half-life extension technology) 2. Rational therapeutic combinations 3. Precision patient selection",
          "pageRefs": null,
          "priority": "Core",
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 00:31:41.367816+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 9,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "8ae7a5c2-aabb-477d-bd18-a3e3cbfdc527",
          "evidence": "Numbered list of strategic pillars",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:31.837+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 9,
          "frameworkName": "list-presentation"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 10,
      "type": "resolution",
      "title": "The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical ",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 74,
        "componentCount": 8,
        "textChars": 628,
        "nDataPoints": 0,
        "notes": "The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.814+00",
          "seconds": 3.133,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/10",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-10",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.32,
            "x": 0.64,
            "y": 0.25
          },
          "kind": "chart",
          "text": "Clinical Precedent: Human Half-Life vs Cyno Half-Life",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Scatter plot",
              "slug": "scatter",
              "status": "active",
              "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "scatter",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "51dad7e2-3861-4d7f-bbe6-d0f16cd845e6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.45,
            "w": 0.25,
            "x": 0.17,
            "y": 0.35
          },
          "kind": "image",
          "text": "Antibody structure diagram",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5eb5f2da-c112-4cfb-98e5-c5db8fecc76b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.18,
            "x": 0.43,
            "y": 0.59
          },
          "kind": "list",
          "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1aac5fec-551c-4800-8b40-abe6200de690",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.18,
            "x": 0.02,
            "y": 0.31
          },
          "kind": "list",
          "text": "Epitopes maintained: Validated pharmacology, Equivalent or better potency",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5de1f719-7576-4dc4-808e-063738831098",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.18,
            "x": 0.02,
            "y": 0.65
          },
          "kind": "list",
          "text": "High concentration SQ: Ability to formulate at >150 mg/mL with low viscosity, Citrate-free formulation",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "81ece246-dfea-4b7a-8536-d7515ffbccfb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.18,
            "x": 0.43,
            "y": 0.36
          },
          "kind": "list",
          "text": "Potential for IP into 2040s: Novel dosing profile, Improved manufacturability, Coverage of diverse back-up series",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f1a57f36-07e6-45ee-93a2-e847deff461f",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.04,
            "w": 0.6,
            "x": 0.2,
            "y": 0.21
          },
          "kind": "title",
          "text": "Spyre mAbs introduce significant improvements over 1st generation mAbs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c9bba45f-5a6d-4791-a609-52621815992d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre mAbs exploit validated biology with modifications designed for best-in-class properties",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "690d57a7-173a-46d9-8a33-8de7c3d6580e",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "de386abd-5724-49f2-805c-518eaad92547",
          "evidence": "Clinical Precedent chart",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:32.814+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 10,
          "frameworkName": "authority-citation"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 11,
      "type": "evidence",
      "title": "Uses a visual metaphor of antibody combination to explain the therapeutic strategy.",
      "function": "cite_precedent",
      "rawType": "why_now",
      "block": null,
      "metadata": {
        "slideType": "why_now",
        "slideTypeCanon": {
          "name": "Why now",
          "slug": "why_now",
          "status": "active",
          "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0",
          "version": 1,
          "description": null
        },
        "function": "cite_precedent",
        "functionCanon": {
          "name": "Cite precedent",
          "slug": "cite_precedent",
          "status": "active",
          "canonId": "019de52d-142b-714b-86d4-58aad7b568ec",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 60,
        "componentCount": 6,
        "textChars": 375,
        "nDataPoints": 3,
        "notes": "Uses a visual metaphor of antibody combination to explain the therapeutic strategy.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.633+00",
          "seconds": 3.95,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/11",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-11",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.3,
            "x": 0.65,
            "y": 0.25
          },
          "kind": "chart",
          "text": "CLINICAL PRECEDENT JNJ VEGA Ph2a study",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Vertical bar chart",
              "slug": "bar-vertical",
              "status": "active",
              "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-vertical",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a064e82e-c37d-435e-ab37-3af479c14d05",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.45,
            "x": 0.05,
            "y": 0.23
          },
          "kind": "diagram",
          "text": "Rational therapeutic combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Process flow",
              "slug": "process",
              "status": "active",
              "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "process",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a4dad79c-99fc-477b-83c5-00b4148e26a0",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.05,
            "y": 0.5
          },
          "kind": "list",
          "text": "Strong single-agent maintenance efficacy; Superior safety profile",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0b2afd1e-19dd-4155-b31a-add2632474a3",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.15,
            "x": 0.48,
            "y": 0.5
          },
          "kind": "list",
          "text": "Strong single-agent induction efficacy; Orthogonal MOA",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "acd004d2-a2e2-426c-888e-6d4fbc44f409",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.4,
            "x": 0.02,
            "y": 0.95
          },
          "kind": "source-note",
          "text": "Source: Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023)",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "cfdd4ef7-be30-45d0-a1eb-f48629f8e27e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is rapidly developing combination products given clinical evidence of substantial efficacy enhancement",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b88d8998-5528-48c7-a96e-e6d5b8836a9f",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "2bc7f346-9db5-46d1-b6fe-8b7c38b79373",
          "evidence": "Cites Lancet Gastroenterol. Hepatol. study to validate the therapeutic strategy.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:33.633+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 11,
          "frameworkName": "authority-citation"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        },
        {
          "to": 11,
          "from": 11,
          "loop": {
            "name": "15_why_now",
            "slug": "15-why-now",
            "status": "active",
            "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
            "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
            "description": "Create temporal urgency by proving that the window of opportunity is opening or closing",
            "familyLabel": null
          },
          "matchId": "8e9697fd-79aa-4fe8-a218-0ec6e1bba9da",
          "evidence": "The document highlights the growing market and the need for improved solutions.",
          "position": 1,
          "objective": "Why now is the right time for Spyre's IBD treatment solutions?",
          "confidence": 0.6,
          "extraction": {
            "at": "2026-07-16 22:37:36.341276+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 12,
      "type": "resolution",
      "title": "The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.",
      "function": "cite_precedent",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "cite_precedent",
        "functionCanon": {
          "name": "Cite precedent",
          "slug": "cite_precedent",
          "status": "active",
          "canonId": "019de52d-142b-714b-86d4-58aad7b568ec",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 60,
        "componentCount": 7,
        "textChars": 259,
        "nDataPoints": 4,
        "notes": "The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.552+00",
          "seconds": 2.853,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/12",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-12",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.32,
            "x": 0.645,
            "y": 0.25
          },
          "kind": "chart",
          "text": "CLINICAL PRECEDENT TL1A studies UC clinical remission at 12 weeks",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Grouped bar chart",
              "slug": "bar-grouped",
              "status": "active",
              "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-grouped",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "eb39f9a5-c72e-4dae-b00f-805a692b8935",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.5,
            "x": 0.05,
            "y": 0.25
          },
          "kind": "diagram",
          "text": "Genetic companion diagnostic (CDx) leveraging large-scale human genomic datasets",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Venn diagram",
              "slug": "venn",
              "status": "active",
              "canonId": "019de52d-0463-710d-b529-cce18d828d2f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "venn",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d7cdb6dd-a9e8-474b-9f1b-8abcf83984ee",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.05,
            "x": 0.82,
            "y": 0.58
          },
          "kind": "metric",
          "text": "20%",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "27bac0f2-43ef-452d-aa25-b840e27c71c5",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.05,
            "x": 0.68,
            "y": 0.55
          },
          "kind": "metric",
          "text": "25%",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d9152ff6-a1b6-443c-89d7-26f9e4e3f3f9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.05,
            "x": 0.89,
            "y": 0.55
          },
          "kind": "metric",
          "text": "27%",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e9474c19-f31a-4393-a94f-37a50f2e56a6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.05,
            "x": 0.75,
            "y": 0.48
          },
          "kind": "metric",
          "text": "38%",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Metric",
              "slug": "metric",
              "status": "active",
              "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d",
              "version": 1,
              "description": "Big-number or KPI value."
            },
            "tool": null,
            "subkind": {
              "name": "Big number",
              "slug": "big-number",
              "status": "active",
              "canonId": "019de52c-fc70-70c8-b965-0584548a9204",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "big-number",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ff2698c3-327c-4777-bb4d-49b0a4df81a1",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre leverages genetically-driven patient selection to match disease drivers with therapeutic targets",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "468d26c0-59ba-411e-b6a2-cbfe09cd19f9",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "65fe2303-8515-47a5-882c-d650c3a276ca",
          "evidence": "Uses clinical precedent data to validate the efficacy of the proposed diagnostic approach.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:32.552+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 12,
          "frameworkName": "authority-citation"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 13,
      "type": "resolution",
      "title": "The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 30,
        "componentCount": 3,
        "textChars": 386,
        "nDataPoints": 0,
        "notes": "The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.083+00",
          "seconds": 3.205,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/13",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-13",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.05,
            "w": 0.9,
            "x": 0.05,
            "y": 0.93
          },
          "kind": "source-note",
          "text": "Spyre holds an option to license worldwide rights from Paragon Therapeutics, Inc. for all programs. SPY003 license is restricted to IBD, all other program licenses are indication agnostic",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d2074e7d-a8eb-4123-a4fc-5c55a88c4215",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.7,
            "w": 0.9,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "table",
          "text": "Pipeline table with columns: Strategy, Target, Program, Discovery, IND-Enabling, Clinical",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d6700df2-1bf4-4533-9297-a56d43a56e8e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "391dd0a6-b49a-4b6b-9a0c-fd3a11bae687",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "029d79b3-a888-49dd-bf84-cdf6a3cc42d0",
          "evidence": "Pipeline development stages visualized over time/status",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 13,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 14,
      "type": "resolution",
      "title": "The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 24,
        "componentCount": 3,
        "textChars": 159,
        "nDataPoints": 4,
        "notes": "The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.199+00",
          "seconds": 2.319,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/14",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-14",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.7,
            "w": 0.9,
            "x": 0.05,
            "y": 0.21
          },
          "kind": "chart",
          "text": "Pipeline development status table",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": "gantt-chart",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1fb1d254-d31c-4c07-b578-a8dd2ac0bc7e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.12,
            "x": 0.79,
            "y": 0.175
          },
          "kind": "legend",
          "text": "Co-lead programs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Legend",
              "slug": "legend",
              "status": "active",
              "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c",
              "version": 1,
              "description": "Color/symbol decoder placed adjacent to a chart or diagram."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "70865874-9ab3-4844-90ae-cf7c88dde018",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "49a3e4e9-199b-4d17-94be-ef36227bd148",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Gantt chart",
            "slug": "gantt-chart",
            "status": "active",
            "bestFor": null,
            "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "ff3482d7-ba69-494a-9742-c9445c816e45",
          "evidence": "chart/gantt-chart: Pipeline development status table",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 00:31:41.592335+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 14,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "4122e329-c419-43f2-ae15-2bc348c3790f",
          "evidence": "Pipeline development stages mapped against programs over time",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:32.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 14,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 15,
      "type": "evidence",
      "title": "Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.",
      "function": "show_traction",
      "rawType": "traction",
      "block": null,
      "metadata": {
        "slideType": "traction",
        "slideTypeCanon": {
          "name": "Traction",
          "slug": "traction",
          "status": "active",
          "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542",
          "version": 1,
          "description": null
        },
        "function": "show_traction",
        "functionCanon": {
          "name": "Show traction",
          "slug": "show_traction",
          "status": "active",
          "canonId": "019de52d-16a8-756a-9b38-a7d35420561d",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 74,
        "componentCount": 7,
        "textChars": 480,
        "nDataPoints": 18,
        "notes": "Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.879+00",
          "seconds": 2.966,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/15",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-15",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.4,
            "w": 0.43,
            "x": 0.05,
            "y": 0.4
          },
          "kind": "chart",
          "text": "Entyvio Global sales (2014-28F)",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Vertical bar chart",
              "slug": "bar-vertical",
              "status": "active",
              "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-vertical",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a5964546-697e-497e-bc2a-29e911bfa2d3",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.4,
            "w": 0.43,
            "x": 0.52,
            "y": 0.4
          },
          "kind": "chart",
          "text": "Entyvio US/EU % market share (June 2014-June 2022)",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7ee93e11-84c4-4cda-87b0-ae9773531b0c",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.5,
            "x": 0.05,
            "y": 0.85
          },
          "kind": "disclaimer",
          "text": "1. Takeda JPM 2023 presentation. Note that Takeda's FY22 is April 2022-March 2023. Sales forecast in figure: EvaluatePharma consensus",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f6977f06-2d84-46a3-8dac-00aa2fe9c6af",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.4,
            "x": 0.05,
            "y": 0.28
          },
          "kind": "list",
          "text": "Vedolizumab estimated $5.4B revenues WW in FY22. Projected to sell $7.5-9.0B at peak WW.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "08cdcd20-0e52-4b2a-b121-b9c282d0a02a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.4,
            "x": 0.52,
            "y": 0.28
          },
          "kind": "list",
          "text": "Significant market share: ~36% of UC market share and ~20% of CD market share in US.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "89cf093f-922a-4ca5-a0d6-f095e18f1d2b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.4,
            "x": 0.3,
            "y": 0.2
          },
          "kind": "quote",
          "text": "Biologic of choice for UC is Entyvio. – US KOL",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Quote",
              "slug": "quote",
              "status": "active",
              "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a",
              "version": 1,
              "description": "Pull quote or testimonial."
            },
            "tool": null,
            "subkind": {
              "name": "Pull quote",
              "slug": "pull-quote",
              "status": "active",
              "canonId": "019de52c-fbf9-76fe-97e1-a0b7540445c9",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "pull-quote",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "fc018550-0b34-466d-9b2f-88ea582f1b27",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.7,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "Vedolizumab is a mega-blockbuster product in IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.879+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e5b2938c-863f-4c76-a91b-bfc2843f39ee",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 15,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 8,
          "name": "Agitate (Make it worse)",
          "beatId": "144f6fae-7163-4a94-a570-0f4d3bd78808",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Agitate (Make it worse)",
            "slug": "problem-agitate-solution-agitate-make-it-worse",
            "status": "active",
            "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456",
            "version": 1,
            "description": null
          },
          "evidence": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments.",
          "position": 1,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Development",
            "slug": "development",
            "status": "active",
            "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1",
            "version": 1,
            "description": "The middle stretch in arcs that have one. Often where length problems creep in."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        },
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 16,
      "type": "setup",
      "title": "The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 69,
        "componentCount": 5,
        "textChars": 1041,
        "nDataPoints": 10,
        "notes": "The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:42.252+00",
          "seconds": 12.279,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/16",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-16",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.45,
            "x": 0.52,
            "y": 0.18
          },
          "kind": "chart",
          "text": "UC Maintenance Efficacy Pbo-adjusted clinical remission %",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Horizontal bar chart",
              "slug": "bar-horizontal",
              "status": "active",
              "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-horizontal",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "569d84ea-3eab-4f59-9b2e-3cccb76075c1",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.35,
            "w": 0.45,
            "x": 0.03,
            "y": 0.33
          },
          "kind": "list",
          "text": "Vedolizumab specifically binds α4β7 integrin, selectively blocking gut lymphocyte trafficking. Leading maintenance efficacy data in UC replicated in two P3 studies; efficacy on par with upadacitinib 15mg dose; superior head-to-head vs adalimumab (Humira) in UC. Clean safety profile since approval in 2014. #1 biologic in IBD bio-naïve patients in the US.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1d3a934f-2025-4f77-a3a5-f98fc4c6e474",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.45,
            "x": 0.03,
            "y": 0.215
          },
          "kind": "quote",
          "text": "“Entyvio (vedolizumab) is the safest drug and one of the most effective for UC.” – US KOL",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Quote",
              "slug": "quote",
              "status": "active",
              "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a",
              "version": 1,
              "description": "Pull quote or testimonial."
            },
            "tool": null,
            "subkind": {
              "name": "Testimonial",
              "slug": "testimonial",
              "status": "active",
              "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "testimonial",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0e26f2bd-74ea-44f5-b1b1-a8839e947f73",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.95,
            "x": 0.03,
            "y": 0.83
          },
          "kind": "source-note",
          "text": "1. Takeda JPM 2023 presentation. Figure data sources: Vedolizumab IV and SC data from VISIBLE 1 P3 study. Ustekinumab, adalimumab, infliximab, golimumab, ozanimod, tofacitinib, upadacitinib data from labels. Mirikizumab data from phase 3 LUCENT-2 study. *Upadacitinib data shown in lighter red is 15mg preferred dose, darker red higher 30mg dose. Maintenance studies shown included patients who achieved clinical response at induction.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "10c73bb2-3a01-443b-b0f1-2042734cc8fa",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "Vedolizumab maintenance efficacy and exquisite safety make it preferred biologic in moderate-to-severe UC",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e6d9f41d-e60b-40d7-9869-b5743b1a7c2a",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Audience Definition",
            "slug": "audience-definition",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756",
            "version": 1,
            "bodyDocId": null,
            "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?",
            "familyLabel": null,
            "categoryName": "Block",
            "categorySlug": "block"
          },
          "agent": "Storyteller",
          "layer": "slide",
          "agents": [
            "Storyteller"
          ],
          "matchId": "113a9096-f157-472f-9fbb-473ccd10ed48",
          "evidence": "The slide mentions 'moderate-to-severe UC' and 'preferred biologic', indicating a specific audience.",
          "pageRefs": null,
          "priority": "Core",
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:41.338738+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 16,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "6c76bd93-aa70-4007-a1cb-35b2bce10d6f",
          "evidence": "The slide compares efficacy and safety across multiple drug classes.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:42.252+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 16,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 17,
      "type": "setup",
      "title": "The slide uses a checkmark/arrow matrix to highlight competitive differentiation.",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 20,
        "componentCount": 3,
        "textChars": 208,
        "nDataPoints": 0,
        "notes": "The slide uses a checkmark/arrow matrix to highlight competitive differentiation.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:32.497+00",
          "seconds": 2.474,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/17",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-17",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.05,
            "w": 0.4,
            "x": 0.02,
            "y": 0.92
          },
          "kind": "disclaimer",
          "text": "*Entyvio SC US BLA resubmitted April 2023 following CRL in 2019.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.497+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7578a51c-baff-4507-9938-fb5daf0fd973",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.75,
            "w": 0.9,
            "x": 0.05,
            "y": 0.15
          },
          "kind": "table",
          "text": "Comparison matrix of SPY001 vs Entyvio IV and SC across 8 clinical/formulation attributes.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.497+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "00632295-2dbf-48bb-a31d-743f10831e62",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.85,
            "x": 0.02,
            "y": 0.03
          },
          "kind": "title",
          "text": "SPY001 is designed to be a best-in-class anti-α4β7 mAb",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:32.497+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c995438a-1cf0-4d89-ae16-38080936ce17",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "2x2 matrix",
            "slug": "matrix-2x2",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
            "version": 1,
            "bodyDocId": null,
            "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "b0d9bccf-cc50-4be4-a375-5454706ebd32",
          "evidence": "The slide contains a table comparing SPY001 with Entyvio IV and SC across 8 clinical/formulation attributes.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 00:31:41.412049+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 17,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "47336e5d-7790-41be-b174-989f3c4ee008",
          "evidence": "Direct feature-by-feature comparison against competitors",
          "framework": null,
          "confidence": 1,
          "extraction": {
            "at": "2026-05-02 11:32:32.497+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 17,
          "frameworkName": "comparison-frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 18,
      "type": "resolution",
      "title": "The slide uses a standard antibody diagram to annotate specific engineering improvements.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 75,
        "componentCount": 7,
        "textChars": 586,
        "nDataPoints": 4,
        "notes": "The slide uses a standard antibody diagram to annotate specific engineering improvements.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.083+00",
          "seconds": 2.915,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/18",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-18",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.85,
            "w": 0.31,
            "x": 0.175,
            "y": 0.3
          },
          "kind": "image",
          "text": "Antibody diagram",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e1a892d9-b3cb-4898-8ac3-53d4fe29bcbc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.52,
            "y": 0.6
          },
          "kind": "list",
          "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3ee8c088-01b0-42b0-b6bf-195713a3568e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.02,
            "y": 0.62
          },
          "kind": "list",
          "text": "High concentration SC: Ability to formulate at >150 mg/mL with low viscosity, Citrate-free formulation may improve patient comfort",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5cafe196-ca0a-4ca6-9538-20cc4dc33d97",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.2,
            "x": 0.52,
            "y": 0.32
          },
          "kind": "list",
          "text": "Potential for IP into 2040s: Diverse coverage of lead and backup series",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8daa7e76-98d9-4125-8fca-bed6062df93b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.02,
            "y": 0.29
          },
          "kind": "list",
          "text": "Epitope maintained: Validated pharmacology, Equivalent potency",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "93bd1d92-9ab7-4f87-bc28-614df6130c32",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.4,
            "w": 0.25,
            "x": 0.7,
            "y": 0.36
          },
          "kind": "table",
          "text": "SPY001 target profile: Efficacy >= vedolizumab, Citrate-free subcutaneous 300 mg dose, Q8W or Q12W dosing interval",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "KPI table",
              "slug": "kpi",
              "status": "active",
              "canonId": "019de52d-0324-7799-a84e-d0885a8ad400",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "kpi",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c8857dc2-16f7-4ee8-a5f1-4579e6548cda",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 exploits validated α4β7 biology with modifications designed for best-in-class properties",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.083+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5e3fcd47-a5d9-440e-b05f-e9500c40e271",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "List presentation",
            "slug": "list-presentation",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1",
            "version": 1,
            "bodyDocId": null,
            "description": "Bulleted, numbered, or checklist enumerations.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "e913d8b8-4c91-41a8-ba6a-1d08fb8822b9",
          "evidence": "The slide uses bullet points to present information about SPY001.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:41.480824+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 18,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 19,
      "type": "resolution",
      "title": "Includes structural visualization of the epitope and two dose-response curves.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 59,
        "componentCount": 6,
        "textChars": 343,
        "nDataPoints": 4,
        "notes": "Includes structural visualization of the epitope and two dose-response curves.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.59+00",
          "seconds": 3.313,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/19",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-19",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.5,
            "w": 0.3,
            "x": 0.32,
            "y": 0.35
          },
          "kind": "chart",
          "text": "Blocking MADCAM-1 Adhesion",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1884c9aa-2f9e-4c0e-aca4-9823660b98da",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.3,
            "x": 0.65,
            "y": 0.35
          },
          "kind": "chart",
          "text": "Blocking VCAM-1 Adhesion",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "78c4502e-6594-4c36-80bb-65a746164e1d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.3,
            "x": 0.02,
            "y": 0.9
          },
          "kind": "disclaimer",
          "text": "1. Results are not based on a head-to-head trial.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4fc0a7cf-6131-47b6-8822-bc9e6d41eafb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.25,
            "x": 0.04,
            "y": 0.38
          },
          "kind": "image",
          "text": "3D protein structure model",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "03847e40-80f0-4645-af4d-b48655ed140b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.96,
            "x": 0.02,
            "y": 0.185
          },
          "kind": "list",
          "text": "SPY001 binds the same α4β7 epitope as vedolizumab. SPY001 is comparable to vedolizumab in potency... ...and avoids unwanted interactions with α4β1.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ccd3bfc7-2ae8-4a46-8108-04dca8246e96",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.75,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 is as potent and selective as vedolizumab in preclinical studies",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3a6f81d1-dbe5-48de-a346-49df4e6cc9d8",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 19,
          "from": 10,
          "loop": {
            "name": "03_aha_moment",
            "slug": "03-aha-moment",
            "status": "active",
            "bestFor": "Data-heavy sections, research findings, analytical arguments",
            "canonId": "019dd956-66f4-7668-ab25-cec9c996c0bc",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Problem/Question -> What the Data Shows -> The Insight",
            "description": "Establish a tension, present data, then deliver the insight that changes everything",
            "familyLabel": null
          },
          "matchId": "81dafa0c-0003-4cb7-a116-4ee57350754d",
          "evidence": "The document presents SPY001 as a potentially best-in-class anti-α4β7 mAb.",
          "position": 0,
          "objective": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?",
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-16 22:37:36.300053+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 20,
      "type": "evidence",
      "title": "The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.",
      "function": "analyze_data",
      "rawType": "traction",
      "block": null,
      "metadata": {
        "slideType": "traction",
        "slideTypeCanon": {
          "name": "Traction",
          "slug": "traction",
          "status": "active",
          "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542",
          "version": 1,
          "description": null
        },
        "function": "analyze_data",
        "functionCanon": {
          "name": "Analyze data",
          "slug": "analyze_data",
          "status": "active",
          "canonId": "019de52d-1590-7413-8c82-cc218cff40b4",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 54,
        "componentCount": 4,
        "textChars": 551,
        "nDataPoints": 12,
        "notes": "The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.131+00",
          "seconds": 2.719,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/20",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-20",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.45,
            "x": 0.05,
            "y": 0.22
          },
          "kind": "chart",
          "text": "Dose-response binding curves for SPY001 and vedolizumab",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.131+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "698bb220-1990-491a-b06d-bb9dc270ff24",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.4,
            "x": 0.55,
            "y": 0.52
          },
          "kind": "list",
          "text": "PBMCs from three human donors were isolated and stained with either vedolizumab or SPY001, as well as a basic immunophenotyping T-cell panel. Both vedolizumab and SPY001 exhibited binding on the memory T-helper CD3+CD4+CD45RO+ population. EC50 values for both antibodies corresponded well with what has previously been reported for binding to the same population: EC50 ~ 0.3 nM.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.131+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f0a993a8-6657-4e35-92c7-2b729d5c99fd",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.4,
            "x": 0.55,
            "y": 0.22
          },
          "kind": "table",
          "text": "EC50 values for Vedolizumab and SPY001 across three donors",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.131+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "407a7b1d-9c3c-41a1-a137-c8e58e6f3140",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.7,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "SPY001 binds to memory T-helper cells as well as vedolizumab",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.131+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f347dc8a-8d01-4caa-a848-90e75451b0a0",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Table data",
            "slug": "table-data",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
            "version": 1,
            "bodyDocId": null,
            "description": "Tabular layouts of structured data.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "56ff7ce2-d4d2-49b9-89a0-7db01a7929a6",
          "evidence": "The slide presents a table with EC50 values for Vedolizumab and SPY001.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:41.584655+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 20,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 21,
      "type": "evidence",
      "title": "The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.",
      "function": "show_traction",
      "rawType": "traction",
      "block": null,
      "metadata": {
        "slideType": "traction",
        "slideTypeCanon": {
          "name": "Traction",
          "slug": "traction",
          "status": "active",
          "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542",
          "version": 1,
          "description": null
        },
        "function": "show_traction",
        "functionCanon": {
          "name": "Show traction",
          "slug": "show_traction",
          "status": "active",
          "canonId": "019de52d-16a8-756a-9b38-a7d35420561d",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 51,
        "componentCount": 4,
        "textChars": 553,
        "nDataPoints": 3,
        "notes": "The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.67+00",
          "seconds": 3.214,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/21",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-21",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.65,
            "w": 0.6,
            "x": 0.02,
            "y": 0.195
          },
          "kind": "chart",
          "text": "Pharmacokinetics in NHP, IV Bolus",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.67+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9c20efea-9bbc-4b32-b9c6-6e266df86f7a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.28,
            "x": 0.68,
            "y": 0.23
          },
          "kind": "list",
          "text": "β-elimination half-life of SPY001 observed at ~17 days, 70% longer than observed for vedolizumab. Spyre vedolizumab data matches half-life observed in Takeda studies.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.67+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d40a8fbc-7581-4306-9629-1cb872479020",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.65,
            "x": 0.12,
            "y": 0.93
          },
          "kind": "source-note",
          "text": "NOTE: 1BLA 125476, Vedolizumab. 2Crawford, D. and Friedman, M. (2019). In all cases, PK data was normalized to Cmax and fit to a biphasic exponential decay curve from which the β-elimination half-life was determined. SOURCE: Data on file.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.67+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9e7b4c99-3aac-4b76-a815-2b9b8916de95",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 has exhibited a 17-day half-life in NHPs, nearly 2x the half-life of vedolizumab observed in multiple studies",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.67+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a7930b63-516f-4e5f-9eac-c4738e59f3fc",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 22,
      "type": "setup",
      "title": "The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 44,
        "componentCount": 4,
        "textChars": 349,
        "nDataPoints": 6,
        "notes": "The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.16+00",
          "seconds": 4.48,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/22",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-22",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.4,
            "w": 0.9,
            "x": 0.05,
            "y": 0.25
          },
          "kind": "chart",
          "text": "Comparison of NHP half-life and predicted human half-life",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Horizontal bar chart",
              "slug": "bar-horizontal",
              "status": "active",
              "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-horizontal",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.16+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e33a81b5-8337-4810-8e13-520bb931ff99",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.9,
            "x": 0.05,
            "y": 0.7
          },
          "kind": "list",
          "text": "YTE modification typically increases mAb half-life by 2-4x versus wild-type in both NHP and human. Human YTE mAb half-life is on average 3.1x of NHP half-life.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.16+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "375bac62-1a77-4c0f-98ba-3741135596d8",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.2,
            "x": 0.02,
            "y": 0.95
          },
          "kind": "source-note",
          "text": "Source: Rosario, M, et. al. (2017).",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.16+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0e314c0b-e0fc-4868-9c9e-beef1eb5a2eb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.75,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 NHP half-life and increased dose suggest potential for significant improvement over Entyvio",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.16+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c3401c04-ded3-44b0-93dc-66c651aeda71",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 23,
      "type": "setup",
      "title": "Uses a visual timeline/comparison to contrast current standard of care with the proposed product.",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 36,
        "componentCount": 4,
        "textChars": 230,
        "nDataPoints": 4,
        "notes": "Uses a visual timeline/comparison to contrast current standard of care with the proposed product.",
        "elementsJson": null,
        "confidence": 0.95,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.59+00",
          "seconds": 2.859,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/23",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-23",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.3,
            "w": 0.9,
            "x": 0.05,
            "y": 0.55
          },
          "kind": "image",
          "text": "SPY001 SC comparison row",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7206d42c-6702-4a24-8045-42f862108c9b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.9,
            "x": 0.05,
            "y": 0.25
          },
          "kind": "image",
          "text": "Vedolizumab SC comparison row",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c9f9b848-444a-42a3-b32d-f482ffb3bea6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.5,
            "x": 0.02,
            "y": 0.88
          },
          "kind": "source-note",
          "text": "Note: Vedolizumab SC approved in EU. US BLA resubmitted April 2023 following CRL in 2019.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d4413830-de26-4b0f-a532-48d543a98ab9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 is specifically formulated to maximize dosing without sacrificing patient comfort",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "02fbe0de-a51e-47ea-9188-bd20f2923bf4",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "fe42138c-85ee-48e2-a0e9-97d117b0469e",
          "evidence": "Direct visual comparison of two products across dosing and comfort metrics.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:33.59+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 23,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 24,
      "type": "setup",
      "title": "The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 68,
        "componentCount": 5,
        "textChars": 851,
        "nDataPoints": 11,
        "notes": "The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.332+00",
          "seconds": 3.561,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/24",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-24",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.55,
            "x": 0.02,
            "y": 0.225
          },
          "kind": "chart",
          "text": "UC induction clinical remission rates",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Vertical bar chart",
              "slug": "bar-vertical",
              "status": "active",
              "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-vertical",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8bfe97c1-c509-41ac-a76e-e07888ba976b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.35,
            "w": 0.38,
            "x": 0.6,
            "y": 0.25
          },
          "kind": "list",
          "text": "Slow onset of vedolizumab efficacy may be explained by insufficient dosing. Clear exposure-efficacy relationship observed at Week 6: Highest quartile achieved a remarkable 37.1% remission rate. Lowest exposure quartile did not separate from placebo.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4dae49d7-064a-46a3-9953-24800281e34f",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.38,
            "x": 0.6,
            "y": 0.6
          },
          "kind": "paragraph",
          "text": "FDA noted \"significant exposure-response relationship\" and recommended exploring higher doses to improve remission rates.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "510fe1a7-fa2e-46ca-91dc-c863f2549b54",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.95,
            "x": 0.02,
            "y": 0.88
          },
          "kind": "source-note",
          "text": "1. Rosario, M., et. al. (2017). 2. Vedolizumab FDA Clinical Pharmacology Review. Figure sources: Multi-MOA benchmark data from adalimumab label (TNFa), ustekinumab label (IL-12/23), mirikizumab LUCENT-1 study (IL-23), PRA023 P2b (TL1A), and vedolizumab VARSITY study (a4b7). Vedolizumab exposure-response data from Rosario, M., et. al. (2017).",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e011e230-abd3-4bb3-9fa8-73ffa20cfa55",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Vedolizumab appears underdosed in induction; opportunity for SPY001 to achieve superior time to onset",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "eab761a5-2646-471e-9755-d6ee812087fb",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "39ec9092-b053-4a31-ab77-36ade4a23238",
          "evidence": "Comparing benchmark MOA data against specific drug exposure quartiles to identify a market opportunity.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:34.332+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 24,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 25,
      "type": "analysis",
      "title": "Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.",
      "function": "analyze_data",
      "rawType": "appendix_data",
      "block": null,
      "metadata": {
        "slideType": "appendix_data",
        "slideTypeCanon": {
          "name": "Appendix data",
          "slug": "appendix_data",
          "status": "active",
          "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd",
          "version": 1,
          "description": null
        },
        "function": "analyze_data",
        "functionCanon": {
          "name": "Analyze data",
          "slug": "analyze_data",
          "status": "active",
          "canonId": "019de52d-1590-7413-8c82-cc218cff40b4",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 47,
        "componentCount": 4,
        "textChars": 403,
        "nDataPoints": 8,
        "notes": "Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:33.62+00",
          "seconds": 2.815,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/25",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-25",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.55,
            "x": 0.03,
            "y": 0.23
          },
          "kind": "chart",
          "text": "Vedolizumab maintenance of clinical remission by exposure quartile",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Vertical bar chart",
              "slug": "bar-vertical",
              "status": "active",
              "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-vertical",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.62+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9fba1b83-56bc-451f-b311-53a79a79dbb1",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.35,
            "x": 0.62,
            "y": 0.35
          },
          "kind": "list",
          "text": "Minimal difference in maintenance of clinical remission between vedolizumab IV Q4W (44.8%) or Q8W (41.8%). Ctrough ≥ 6 µg/mL is a conservative target to maintain long-term efficacy with potent anti-α4β7 mAbs.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.62+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e333cedd-df34-4089-a138-a3c3ac13bfba",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.15,
            "x": 0.02,
            "y": 0.95
          },
          "kind": "source-note",
          "text": "Source: Feagan, et. al. (2013).",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.62+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "11727fd6-d261-4b2a-af9f-40dcdf392856",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.7,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Once induction is achieved, very low exposures of vedolizumab are sufficient to maintain remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:33.62+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1b465f25-d1e9-40a9-9af5-2c91c84e0007",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 26,
      "type": "resolution",
      "title": "The slide uses a 2x2 grid to summarize the program's value proposition.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 74,
        "componentCount": 7,
        "textChars": 558,
        "nDataPoints": 3,
        "notes": "The slide uses a 2x2 grid to summarize the program's value proposition.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.844+00",
          "seconds": 3.332,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/26",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-26",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.45,
            "x": 0.4,
            "y": 0.75
          },
          "kind": "chart",
          "text": "UPCOMING CATALYSTS",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": "timeline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b83710f3-02f5-431a-a5cb-83e847f843e4",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.55,
            "w": 0.28,
            "x": 0.04,
            "y": 0.25
          },
          "kind": "image",
          "text": "SPY001 antibody illustration",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a30e23b9-1f04-4b3a-8c47-f44243191d33",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.28,
            "x": 0.66,
            "y": 0.235
          },
          "kind": "list",
          "text": "Clinically validated pharmacology: SPY001 observed to maintain vedolizumab's epitope with similar potency",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3181683b-641d-4fee-b1f4-74204f79b9cf",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.28,
            "x": 0.36,
            "y": 0.235
          },
          "kind": "list",
          "text": "Preferred target in large market: Vedolizumab is the preferred biologic in UC with >$5B in annual sales",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6b3daad4-ca2f-4f3b-b39f-669ade628b0a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.28,
            "x": 0.66,
            "y": 0.46
          },
          "kind": "list",
          "text": "Promising early data: SPY001 observed to match vedolizumab's potency and selectivity and has ~2x half-life in NHPs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6bf6fbca-84a7-4b1e-9a1e-51bc56b99eb8",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.28,
            "x": 0.36,
            "y": 0.46
          },
          "kind": "list",
          "text": "Designed for differentiation: Q8W+ dosing, faster time to onset, patient-friendly formulation",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ee3a8549-d9d5-47a4-81b3-f88df00a82ad",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY001 is a potentially best-in-class anti-α4β7 mAb with near-term de-risking studies anticipated",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8e3758bd-5e65-4085-929f-c3224e9a6841",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "b2212ef8-30cc-4dcc-8622-3dbf86cc7012",
          "evidence": "The program summary is organized into a 2x2 grid of key value propositions.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:34.844+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 26,
          "frameworkName": "matrix-2x2"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 27,
      "type": "setup",
      "title": "The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.",
      "function": "compare_peers",
      "rawType": "peer_benchmark",
      "block": null,
      "metadata": {
        "slideType": "peer_benchmark",
        "slideTypeCanon": {
          "name": "Peer benchmark",
          "slug": "peer_benchmark",
          "status": "active",
          "canonId": "019de52d-08f0-7158-a78d-d7b5331fefaf",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 47,
        "componentCount": 4,
        "textChars": 409,
        "nDataPoints": 6,
        "notes": "The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.444+00",
          "seconds": 2.859,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/27",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-27",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.35,
            "w": 0.92,
            "x": 0.04,
            "y": 0.17
          },
          "kind": "chart",
          "text": "Market cap comps at key events: Projected",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Grouped bar chart",
              "slug": "bar-grouped",
              "status": "active",
              "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-grouped",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.444+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "75eb36d9-6faa-4fbe-828b-b8c24abd74b5",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.96,
            "x": 0.02,
            "y": 0.58
          },
          "kind": "diagram",
          "text": "Projected 2023-2025+ timeline with SPY001 milestones",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Timeline",
              "slug": "timeline",
              "status": "active",
              "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "timeline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.444+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c4be594a-a5d9-42cc-b81a-57b1baee853b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.75,
            "x": 0.12,
            "y": 0.94
          },
          "kind": "source-note",
          "text": "Source: FactSet 30-d average market caps after event date. 1 Morphic Phase 2a single arm UC data; Prometheus RCT (UC) and single arm (CD) Phase 2.; Prometheus ultimately acquired for $10.8B after Phase 2 data",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.444+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "486ab404-670c-4d50-9023-5a03a9dfef9b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Key value inflection in ~18 months with Phase 1 PK data anticipated to validate SPY001 as “long-acting Vedo”",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.444+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7e506f72-4d5c-4b53-8f31-5e5fdaa8aaf4",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "5fd75906-0f10-4bbe-8138-c2d77af66ec1",
          "evidence": "Comparison of market cap at clinical milestones",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:34.444+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 27,
          "frameworkName": "peer_benchmark"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 28,
      "type": "setup",
      "title": "The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 17,
        "componentCount": 2,
        "textChars": 152,
        "nDataPoints": 2,
        "notes": "The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.405+00",
          "seconds": 2.791,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/28",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-28",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.65,
            "w": 0.92,
            "x": 0.04,
            "y": 0.224
          },
          "kind": "table",
          "text": "Agent, MOA, Indication, Administration, Efficacy, Safety",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.405+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f9f7965c-d581-45af-91fe-6af5a7256ae4",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "A conservative SPY001 product profile was tested against Takeda’s Entyvio and Morphic’s MORF-057",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.405+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "aaa99f97-2349-48c0-b8b7-eb7bc17ad071",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Comparison frame",
            "slug": "comparison-frame",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93",
            "version": 1,
            "bodyDocId": null,
            "description": "Two or more states/subjects placed side by side to expose a gap.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "70ab07c1-f54f-4426-92c3-627abb7108ad",
          "evidence": "table/data: Agent, MOA, Indication, Administration, Efficacy, Safety",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 03:39:02.809521+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 28,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "7ffa6f07-a313-4593-af65-f998d0e2e720",
          "evidence": "The slide uses a structured table to compare the subject product against two direct competitors.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:34.405+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 28,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [
        {
          "to": 28,
          "from": 28,
          "loop": {
            "name": "47_quick_win_big_bet",
            "slug": "47-quick-win-big-bet",
            "status": "active",
            "bestFor": "Transformation planning, 100-day plans, resource allocation",
            "canonId": "019dd956-790d-708d-983e-ef9bbc68f741",
            "version": 1,
            "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21",
            "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
            "description": "Separate initiatives into immediate wins and longer-term strategic bets",
            "familyLabel": null
          },
          "matchId": "97dc64e0-9ee7-4111-9a96-eee5c2c2a6af",
          "evidence": "The document presents Spyre's plan to rapidly advance combination programs.",
          "position": 2,
          "objective": "What if Spyre's combination programs could create optimal combinations in IBD?",
          "confidence": 0.6,
          "extraction": {
            "at": "2026-07-16 22:37:36.381816+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": "doc-narrative-v1"
          }
        }
      ],
      "locked": true
    },
    {
      "page": 29,
      "type": "evidence",
      "title": "The chart compares preference share between Naïve and Switch patients for four different drug profiles.",
      "function": "cite_precedent",
      "rawType": "testimonial",
      "block": null,
      "metadata": {
        "slideType": "testimonial",
        "slideTypeCanon": {
          "name": "Testimonial",
          "slug": "testimonial",
          "status": "active",
          "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97",
          "version": 1,
          "description": null
        },
        "function": "cite_precedent",
        "functionCanon": {
          "name": "Cite precedent",
          "slug": "cite_precedent",
          "status": "active",
          "canonId": "019de52d-142b-714b-86d4-58aad7b568ec",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 70,
        "componentCount": 6,
        "textChars": 573,
        "nDataPoints": 8,
        "notes": "The chart compares preference share between Naïve and Switch patients for four different drug profiles.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.446+00",
          "seconds": 2.776,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/29",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-29",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.35,
            "x": 0.05,
            "y": 0.25
          },
          "kind": "chart",
          "text": "Preference class share in naïve and experienced patients",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Stacked bar chart (100%)",
              "slug": "bar-stacked-100pct",
              "status": "active",
              "canonId": "019de52c-ff14-71b8-8d88-860f8d7da84b",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-stacked-100pct",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "610d2f6e-e797-44f2-965e-632b3e4e05af",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.4,
            "x": 0.55,
            "y": 0.25
          },
          "kind": "quote",
          "text": "Oral agents typically have an advantage except in this case ... one shot every three months will have the advantage",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Quote",
              "slug": "quote",
              "status": "active",
              "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a",
              "version": 1,
              "description": "Pull quote or testimonial."
            },
            "tool": null,
            "subkind": {
              "name": "Testimonial",
              "slug": "testimonial",
              "status": "active",
              "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "testimonial",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0fc058eb-dfe2-4e1b-9898-bf666ac14d7f",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.4,
            "x": 0.55,
            "y": 0.45
          },
          "kind": "quote",
          "text": "Infrequent injections are more beneficial than orals, patients will forget to take the orals daily",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Quote",
              "slug": "quote",
              "status": "active",
              "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a",
              "version": 1,
              "description": "Pull quote or testimonial."
            },
            "tool": null,
            "subkind": {
              "name": "Testimonial",
              "slug": "testimonial",
              "status": "active",
              "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "testimonial",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "55b87bc4-198a-4f47-9d51-dfc61af2850a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.4,
            "x": 0.55,
            "y": 0.65
          },
          "kind": "quote",
          "text": "The denominator will also increase with this profile, I would expect more patients to go to [SPY001] rather than Stelara after TNF failure",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Quote",
              "slug": "quote",
              "status": "active",
              "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a",
              "version": 1,
              "description": "Pull quote or testimonial."
            },
            "tool": null,
            "subkind": {
              "name": "Testimonial",
              "slug": "testimonial",
              "status": "active",
              "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "testimonial",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d7bc0e60-850a-40a4-8c48-dbe96fc623de",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.4,
            "x": 0.03,
            "y": 0.9
          },
          "kind": "source-note",
          "text": "Source: Expert calls with N=14 gastroenterologists conducted in May 2023",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "edab9380-e416-4e68-9a79-53054f0f9aea",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.03,
            "y": 0.05
          },
          "kind": "title",
          "text": "Assuming equivalent efficacy and safety, a quarterly injectable would be the preferred profile",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "32bd9643-b993-493e-ab7a-ab76fd6c7b31",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "2af25032-38e6-4757-9dbf-5cfa37c60668",
          "evidence": "Using KOL quotes to validate market preference",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:34.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 29,
          "frameworkName": "authority-citation"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 30,
      "type": "resolution",
      "title": "The slide uses a Gantt-style pipeline visualization to show progress from discovery to clinical stages for seven distinct programs.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 17,
        "componentCount": 3,
        "textChars": 159,
        "nDataPoints": 0,
        "notes": "The slide uses a Gantt-style pipeline visualization to show progress from discovery to clinical stages for seven distinct programs.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.106+00",
          "seconds": 5.409,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/30",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-30",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.7,
            "w": 0.9,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "chart",
          "text": "Pipeline development status table",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": "gantt-chart",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.106+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6c2fd47a-4c04-43e1-a355-bf2724715271",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.12,
            "x": 0.79,
            "y": 0.17
          },
          "kind": "legend",
          "text": "Co-lead programs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Legend",
              "slug": "legend",
              "status": "active",
              "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c",
              "version": 1,
              "description": "Color/symbol decoder placed adjacent to a chart or diagram."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.106+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "39f279c0-9104-4bfa-840a-35d07723a109",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.106+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b5b17aa1-ab5a-492c-9e0b-708eb0e7c854",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Gantt chart",
            "slug": "gantt-chart",
            "status": "active",
            "bestFor": null,
            "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "6bdc0443-1595-449a-9162-0fcef8d0a33b",
          "evidence": "The slide contains a Gantt chart showing pipeline development status.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 03:39:05.611547+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 30,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "258b2ac4-f3fe-45b6-bbde-528e89482f9d",
          "evidence": "Pipeline visualization showing stages of development over time",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:37.106+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 30,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 31,
      "type": "setup",
      "title": "The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 76,
        "componentCount": 6,
        "textChars": 820,
        "nDataPoints": 12,
        "notes": "The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:34.75+00",
          "seconds": 2.943,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/31",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-31",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.45,
            "x": 0.05,
            "y": 0.65
          },
          "kind": "callout",
          "text": "First-generation anti-TL1A antibodies provide blueprint for a next-generation best-in-class agent from Spyre.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5fe72eac-1d10-46cd-88fa-fb831a7032c6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.45,
            "x": 0.05,
            "y": 0.5
          },
          "kind": "callout",
          "text": "Phase 2 results in UC and CD with PRA023 was a key factor in Prometheus’ $10.8B acquisition by Merck.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ec824271-39c6-4bc6-9611-6970232d4fca",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.65,
            "w": 0.45,
            "x": 0.52,
            "y": 0.18
          },
          "kind": "chart",
          "text": "UC Induction Efficacy Pbo-adjusted clinical remission %",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Horizontal bar chart",
              "slug": "bar-horizontal",
              "status": "active",
              "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-horizontal",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e028daa0-255a-4ae0-9950-4d4c49e44611",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.45,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "list",
          "text": "TL1A is involved in chronic inflammation and fibrosis pathways and is genetically associated with IBD. Clinical results from first-generation anti-TL1A antibodies suggest potential for highest induction efficacy across target classes.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5a682d71-bcc4-47b2-8938-9475868e7d93",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.9,
            "x": 0.05,
            "y": 0.88
          },
          "kind": "source-note",
          "text": "Figure data sources: PRA023 P2b study. RVT-3101 P2b study. Vedolizumab GEMINI 1 P3 study. Ustekinumab, adalimumab, infliximab, risankizumab golimumab, ozanimod, tofacitinib, upadacitinib data from labels. Mirikizumab data from phase 3 LUCENT-1 study.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5433b1b6-a73a-4389-a10e-d60d839063c6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.6,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "TL1A has emerged as one of the most promising targets in both UC and CD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:34.75+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "2b97a62a-2f7a-45f8-a068-7587ce4ac271",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 32,
      "type": "setup",
      "title": "The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 40,
        "componentCount": 3,
        "textChars": 421,
        "nDataPoints": 8,
        "notes": "The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.208+00",
          "seconds": 3.002,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/32",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-32",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.9,
            "x": 0.02,
            "y": 0.85
          },
          "kind": "source-note",
          "text": "1. Prometheus PRA023 P2 ARTEMIS-UC and P2a APOLLO-CD data readouts... 2. Roivant RVT-3101 Release Deck... 3. Teva's TEV-48574 TL1A is currently in Phase 2 IBD studies...",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.208+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "cfbbdd34-30e2-428b-b0a9-b71005f58dd2",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.65,
            "w": 0.95,
            "x": 0.02,
            "y": 0.2
          },
          "kind": "table",
          "text": "Comparison matrix of 4 drugs across 7 attributes: Complete TL1A blockade, Highly potent, Infrequent SC dosing, Convenient formulation, High remission rates, Favorable safety profile, Immunogenicity.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.208+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "bd2c9562-5a31-4d71-bae1-fdfb8ac79a07",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY002 is designed to be a best-in-class anti-TL1A mAb",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.208+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "76372f29-d523-4ef4-a7b1-063ead438ead",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "2x2 matrix",
            "slug": "matrix-2x2",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
            "version": 1,
            "bodyDocId": null,
            "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "3886e431-5a42-489d-92a1-70c2da461af5",
          "evidence": "The slide contains a table comparing attributes of multiple drugs.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:05.72538+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 32,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "de734179-f3c0-4f1a-9cf1-3da9ea5f74c3",
          "evidence": "The slide presents a structured grid comparing product attributes across multiple competitors.",
          "framework": null,
          "confidence": 1,
          "extraction": {
            "at": "2026-05-02 11:32:35.208+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 32,
          "frameworkName": "comparison_table"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 33,
      "type": "resolution",
      "title": "The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 74,
        "componentCount": 7,
        "textChars": 556,
        "nDataPoints": 3,
        "notes": "The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).",
        "elementsJson": null,
        "confidence": 0.95,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.072+00",
          "seconds": 3.804,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/33",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-33",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.35,
            "w": 0.31,
            "x": 0.173,
            "y": 0.3
          },
          "kind": "image",
          "text": "Antibody diagram",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1283462c-7c29-46ed-9cfe-8ce087fb5327",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.53,
            "y": 0.6
          },
          "kind": "list",
          "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "815d692b-dade-4eb2-b2ff-1088e524aa15",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.1,
            "x": 0.53,
            "y": 0.29
          },
          "kind": "list",
          "text": "Novel into 2040s",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "84a2b3d1-7fcf-403c-ab43-05bcb086abd8",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.2,
            "x": 0.02,
            "y": 0.62
          },
          "kind": "list",
          "text": "High concentration SC: Ability to formulate at >150 mg/mL with low viscosity; Citrate-free formulation may improve patient comfort",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "906c449c-6a87-4d6e-98f0-4723fab90930",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.15,
            "x": 0.02,
            "y": 0.3
          },
          "kind": "list",
          "text": "PRA023 clinically validates pharmacology and therapeutic effect of MOA",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "fe31c758-a45d-48c3-a5fa-62c31d218023",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.25,
            "x": 0.71,
            "y": 0.39
          },
          "kind": "table",
          "text": "SPY002 target profile: Efficacy >= PRA023; Subcutaneous 300 mg dose; Q8W or Q12W dose with citrate-free, patient-friendly formulation",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "KPI table",
              "slug": "kpi",
              "status": "active",
              "canonId": "019de52d-0324-7799-a84e-d0885a8ad400",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "kpi",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "787fe6d4-191b-4eb9-a6d0-64db3664a898",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.78,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY002 exploits biology that has been validated by PRA023 and is designed to be best-in-class",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.072+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8216cd55-f5a8-4b44-8bfe-8b90999a3669",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 34,
      "type": "setup",
      "title": "The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development",
      "function": "compare_peers",
      "rawType": "competitive_analysis",
      "block": null,
      "metadata": {
        "slideType": "competitive_analysis",
        "slideTypeCanon": {
          "name": "Competitive analysis",
          "slug": "competitive_analysis",
          "status": "active",
          "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 62,
        "componentCount": 5,
        "textChars": 647,
        "nDataPoints": 2,
        "notes": "The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:38.808+00",
          "seconds": 6.529,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/34",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-34",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.25,
            "w": 0.45,
            "x": 0.5,
            "y": 0.475
          },
          "kind": "callout",
          "text": "Spyre is advancing both monomeric/trimeric and trimeric-only TL1A mAbs to DC selection. Redundancy provides highest probability of creating a best-in-class therapeutic.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "de272141-efc7-4a13-ada0-f09cbe434c23",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.4,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "chart",
          "text": "UC induction clinical remission rates Pbo-adjusted %",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Vertical bar chart",
              "slug": "bar-vertical",
              "status": "active",
              "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-vertical",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f8743d66-1d47-41f4-893c-c5a25d8c2151",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.48,
            "x": 0.48,
            "y": 0.22
          },
          "kind": "list",
          "text": "Though PRA023 performed numerically better in a cross-trial comparison, it has yet to be determined whether monomeric/trimeric blockade is superior. Known biology suggests only trimeric blockade is necessary for effect.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "798936b3-a03a-4448-b035-17493426127b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.7,
            "x": 0.05,
            "y": 0.9
          },
          "kind": "source-note",
          "text": "Figure sources: Prometheus PRA023 P2 ARTEMIS-UC data release, December 7, 2022. Roivant RVT-3101 Release Deck, January 4, 2023.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e4cb9970-eab5-4d30-a537-246aff332f04",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.7,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is evaluating both trimeric and monomeric/trimeric TL1A blockade for SPY002",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "39bf396a-78c7-4cbf-8704-854afb962bfd",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "77c77703-0f83-440c-b1d1-156a07a8bb12",
          "evidence": "Comparing two different therapeutic approaches (monomeric/trimeric vs trimeric-only) to justify a dual-track strategy.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:38.808+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 34,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 35,
      "type": "setup",
      "title": "The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.",
      "function": "present_solution",
      "rawType": "product_demo",
      "block": null,
      "metadata": {
        "slideType": "product_demo",
        "slideTypeCanon": {
          "name": "Product demo",
          "slug": "product_demo",
          "status": "active",
          "canonId": "019de52d-0f06-7288-84f2-7568c1020fce",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 64,
        "componentCount": 5,
        "textChars": 627,
        "nDataPoints": 12,
        "notes": "The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.228+00",
          "seconds": 2.88,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/35",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-35",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.4,
            "w": 0.3,
            "x": 0.03,
            "y": 0.37
          },
          "kind": "chart",
          "text": "Dose-response curve showing % Inhibition of TF-1 Apoptosis vs Antibody Concentration",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.228+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b1d880c8-16e7-4115-9ad4-87b8d592d89b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.4,
            "w": 0.3,
            "x": 0.35,
            "y": 0.37
          },
          "kind": "chart",
          "text": "Scatter plot showing Relative DcR3/DR3 Blocking vs TF-1 Apoptosis Inhibition IC50",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Scatter plot",
              "slug": "scatter",
              "status": "active",
              "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "scatter",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.228+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6c300913-5100-4478-9b3f-bc258d684a15",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.28,
            "x": 0.7,
            "y": 0.2
          },
          "kind": "list",
          "text": "Spyre has multiple lead clones that have demonstrated superior potency as compared to PRA023. Diverse clones identified matching specificity profile with competitive antibodies. Development candidate to optimize against trimer and monomers, selectivity against decoy receptor.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.228+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "61331a3d-ec5d-4ba0-bc9d-a1fcd5f1ede9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.9,
            "x": 0.05,
            "y": 0.85
          },
          "kind": "paragraph",
          "text": "Specialized reagents required to generate monomeric/trimeric TL1A mAbs, likely limiting fast-follower competition",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.228+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "affc7c10-9758-4daa-a583-a657cfe65bd7",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.65,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "De novo TL1A lead clones are highly potent and characteristically diverse",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.228+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b4bc3b69-6817-4068-97ce-785947355aee",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 36,
      "type": "resolution",
      "title": "The slide uses a 2x2 grid to summarize the program's value proposition.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 66,
        "componentCount": 7,
        "textChars": 521,
        "nDataPoints": 0,
        "notes": "The slide uses a 2x2 grid to summarize the program's value proposition.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.858+00",
          "seconds": 3.226,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/36",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-36",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.5,
            "x": 0.4,
            "y": 0.72
          },
          "kind": "diagram",
          "text": "UPCOMING CATALYSTS",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Timeline",
              "slug": "timeline",
              "status": "active",
              "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "timeline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3166e869-58cb-4d21-a36c-8a31a8e1eb53",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.28,
            "x": 0.04,
            "y": 0.25
          },
          "kind": "image",
          "text": "Antibody diagram",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "da84a8ed-a5c2-44ec-ab44-8c46cb37c0c0",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.28,
            "x": 0.36,
            "y": 0.46
          },
          "kind": "list",
          "text": "Designed for differentiation: Q8W+ dosing and formulation improvements",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6826a12f-f3c1-407c-a5c2-6f13cff0ac16",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.28,
            "x": 0.66,
            "y": 0.24
          },
          "kind": "list",
          "text": "Clinically validated pharmacology: SPY002 conserves the validated epitope to maximize TL1A blockade",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "89ed53d7-c6c7-4b75-8a18-58c7d32aebf1",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.28,
            "x": 0.66,
            "y": 0.46
          },
          "kind": "list",
          "text": "Promising early data: SPY002 observed to bind to monomers and trimers with picomolar potency",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9115f525-b655-4cbd-aec5-454726be64b9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.28,
            "x": 0.36,
            "y": 0.24
          },
          "kind": "list",
          "text": "Attractive target in a large market: Existing investigational products have demonstrated excellent clinical efficacy in UC and CD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ab2525f3-b5de-44a7-a837-c67e7a34b8b4",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.75,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "SPY002 is a potentially best-in-class anti-TL1A mAb with near-term de-risking studies anticipated",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e5ae38f6-5da0-40e9-ae1f-60e8b3605794",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "88aa400c-e5dc-4cf5-a049-966112b1a699",
          "evidence": "The program summary is organized into a 2x2 grid of key value propositions.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:35.858+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 36,
          "frameworkName": "matrix-2x2"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 37,
      "type": "resolution",
      "title": "The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 15,
        "componentCount": 3,
        "textChars": 135,
        "nDataPoints": 0,
        "notes": "The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.",
        "elementsJson": null,
        "confidence": 0.9,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.4+00",
          "seconds": 4.555,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/37",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-37",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.65,
            "w": 0.88,
            "x": 0.11,
            "y": 0.2
          },
          "kind": "diagram",
          "text": "IBD, SSc-ILD, Expansion I&I indications",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Process flow",
              "slug": "process",
              "status": "active",
              "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "process",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.4+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a90757aa-9dd9-4653-8285-9e01a03f7046",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.18,
            "x": 0.08,
            "y": 0.28
          },
          "kind": "image",
          "text": null,
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.4+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "fda3cfc4-ce6a-4f89-bc3a-99c6661f84ad",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "TL1A: Potential I&I indication expansion with dual anti-fibrotic and anti-inflammatory mechanism",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.4+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0302adae-d0e1-499d-a541-a3772f898e06",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "66f35c30-ae38-4553-8f4b-a2ac92bf316a",
          "evidence": "Sequential progression of indications shown as rising peaks",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:37.4+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 37,
          "frameworkName": "roadmap"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 38,
      "type": "resolution",
      "title": "The slide uses a Gantt-style visualization to show the progression of various IBD programs.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 16,
        "componentCount": 3,
        "textChars": 152,
        "nDataPoints": 0,
        "notes": "The slide uses a Gantt-style visualization to show the progression of various IBD programs.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.661+00",
          "seconds": 2.527,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/38",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-38",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.7,
            "w": 0.9,
            "x": 0.05,
            "y": 0.215
          },
          "kind": "chart",
          "text": "Pipeline development chart",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": "gantt-chart",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.661+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0166279e-af25-4463-9254-531b562b9851",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.1,
            "x": 0.79,
            "y": 0.175
          },
          "kind": "legend",
          "text": "Co-lead programs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Legend",
              "slug": "legend",
              "status": "active",
              "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c",
              "version": 1,
              "description": "Color/symbol decoder placed adjacent to a chart or diagram."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.661+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "973d638e-1745-439c-a3dd-e14b91155594",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.661+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "884fb8b6-d5c8-4d05-93c1-d80848ca8ebe",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Gantt chart",
            "slug": "gantt-chart",
            "status": "active",
            "bestFor": null,
            "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "d465248c-e35f-4ea4-a5ab-17c96284d01a",
          "evidence": "The slide contains a Gantt chart showing pipeline development status.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 03:39:05.982581+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 38,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "0cfad16c-3b5c-43e4-bf21-00c700e4a09a",
          "evidence": "Visual representation of project timelines and stages",
          "framework": null,
          "confidence": 1,
          "extraction": {
            "at": "2026-05-02 11:32:35.661+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 38,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 39,
      "type": "resolution",
      "title": "The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 45,
        "componentCount": 4,
        "textChars": 546,
        "nDataPoints": 0,
        "notes": "The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:35.937+00",
          "seconds": 2.496,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/39",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-39",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.06,
            "w": 0.96,
            "x": 0.02,
            "y": 0.86
          },
          "kind": "callout",
          "text": "Spyre is a pioneer in developing best-in-class mAbs against three top targets to enable superior combinations for IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.937+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5b33621b-d442-4f30-b8d3-4dfce76d9a9d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.96,
            "x": 0.02,
            "y": 0.25
          },
          "kind": "image",
          "text": "Biological mechanism diagram showing T-cell trafficking, colonic fibrosis, and inflammatory cascades.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.937+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ae5bf3c8-2286-474f-a875-f4fa76816a13",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.06,
            "w": 0.96,
            "x": 0.02,
            "y": 0.18
          },
          "kind": "paragraph",
          "text": "Blockade of a4b7 prevents circulating T cells from entering inflammatory gut tissues. Neutralization of TL1A suppresses inflammation within the gut tissue and blocks immune cell activation. Neutralization of IL-23 inhibits cascade of various proinflammatory cytokines.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.937+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3f0f8fac-3e95-4d0e-9e18-a4371430c66e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre portfolio addresses the diverse pathophysiology of IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:35.937+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "edc7144a-9eb9-4f34-9ff8-b89c9c853e51",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 40,
      "type": "setup",
      "title": "The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 64,
        "componentCount": 5,
        "textChars": 628,
        "nDataPoints": 12,
        "notes": "The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.105+00",
          "seconds": 3.514,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/40",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-40",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.25,
            "w": 0.335,
            "x": 0.645,
            "y": 0.325
          },
          "kind": "callout",
          "text": "Despite non-optimal components, JNJ combination (JNJ-78934804) delivered superior UC efficacy compared to any single agent. Spyre aims to build on this success with combinations of best-in-class mAbs from superior MOAs.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "122bf700-025e-4067-b402-c0f2342c5c8a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.35,
            "w": 0.45,
            "x": 0.12,
            "y": 0.25
          },
          "kind": "chart",
          "text": "Clinical remission rates (induction) for Golimumab, Guselkumab, and Combination",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Stacked bar chart",
              "slug": "bar-stacked",
              "status": "active",
              "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-stacked",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "37cd5cc3-78c8-46bd-b920-a3464a151248",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.8,
            "x": 0.02,
            "y": 0.89
          },
          "kind": "source-note",
          "text": "NOTE: *In VEGA, only guselkumab (IL-23) was continued in maintenance for the combo arm in a treat-through design; Spyre plans to use combinations in maintenance.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "75eab2c5-f334-4226-aa6f-10aa5e0110a2",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.55,
            "x": 0.02,
            "y": 0.63
          },
          "kind": "table",
          "text": "Table showing N, Maintenance remission, and Safety for the three groups",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8deaaac7-7b10-4253-87a9-84d8100d98a6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "JNJ's VEGA study demonstrated power of combination therapy despite relative weakness of components",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "cbc75fd8-fd0b-401f-b41b-9f333773631f",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "5f6d4669-5ccc-4861-a108-d4868f8f0645",
          "evidence": "Comparing single agents vs combination therapy efficacy",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:37.105+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 40,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 41,
      "type": "setup",
      "title": "The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 72,
        "componentCount": 9,
        "textChars": 328,
        "nDataPoints": 6,
        "notes": "The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.579+00",
          "seconds": 2.965,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/41",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-41",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.25,
            "y": 0.45
          },
          "kind": "chart",
          "text": ">50% remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0b08cf16-8e22-45dd-991f-7d84a23cf7d5",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.45,
            "y": 0.45
          },
          "kind": "chart",
          "text": "TBD remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "111026ca-c00b-4097-adb9-938fd53e2c5e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.45,
            "y": 0.25
          },
          "kind": "chart",
          "text": "48% remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "2da2021b-e53b-4913-92c9-78dbb6e2acbb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.25,
            "y": 0.65
          },
          "kind": "chart",
          "text": ">50% remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5017755b-b5f0-4dd8-937d-8f52b58d925d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.45,
            "y": 0.65
          },
          "kind": "chart",
          "text": ">50% remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "51c11f15-4c86-4b1f-bc3b-78e31889571e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.1,
            "x": 0.25,
            "y": 0.25
          },
          "kind": "chart",
          "text": "47% remission",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Donut chart",
              "slug": "donut",
              "status": "active",
              "canonId": "019de52d-0006-752c-9528-0fef476b8004",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "donut",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e5b381f4-f420-400c-8125-a45fcc0f329b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.5,
            "x": 0.12,
            "y": 0.94
          },
          "kind": "disclaimer",
          "text": "The figures above are for illustrative purposes only, assuming combinations result in additive efficacy",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Disclaimer",
              "slug": "disclaimer",
              "status": "active",
              "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc",
              "version": 1,
              "description": "Legal/cautionary text that occupies most of the body of its slide."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "af102aae-61aa-4b81-a860-ef5880ab0151",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.9,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "table",
          "text": "Program, UC Induction, UC Maintenance, Safety, Dosing",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "68b95086-a48f-4b3e-8773-fccbb3103ba5",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.75,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre could create optimal combinations in IBD to safely and conveniently maximize efficacy",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1915a4ac-289e-416f-b8a3-6d6717f36e23",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "1125a9ae-76a4-46cc-b622-acbd6419b761",
          "evidence": "Table comparing programs across efficacy, safety, and dosing metrics.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:36.579+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 41,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 42,
      "type": "resolution",
      "title": "The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 30,
        "componentCount": 4,
        "textChars": 251,
        "nDataPoints": 0,
        "notes": "The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.847+00",
          "seconds": 3.145,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/42",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-42",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.07,
            "w": 0.58,
            "x": 0.39,
            "y": 0.8
          },
          "kind": "callout",
          "text": "Comparable development strategy to be pursued with SPY002 (TL1A) combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.847+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5f97448d-2277-404d-a7b2-b62d4ce980bc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.65,
            "w": 0.96,
            "x": 0.02,
            "y": 0.185
          },
          "kind": "diagram",
          "text": "Phase 1 to Phase 3 clinical trial progression",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Process flow",
              "slug": "process",
              "status": "active",
              "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "process",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.847+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d871339d-6436-46c5-8230-31bbd794d73d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.25,
            "x": 0.02,
            "y": 0.89
          },
          "kind": "source-note",
          "text": "Preliminary; pending regulatory feedback",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.847+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b03ccbaa-af1d-47c3-adf8-cc0121d7521b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.75,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "We plan to rapidly advance combination programs in parallel with monotherapies in Phase 2",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.847+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f78139e0-ab4f-4b12-a9ed-ddc37d33cf24",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Three horizons (McKinsey)",
            "slug": "three-horizons",
            "status": "active",
            "bestFor": null,
            "canonId": "019de52d-1a3c-72cc-b532-f52d3e454a83",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "60b81bcf-619c-40a1-a097-53b6f11c4d25",
          "evidence": "We plan to rapidly advance combination programs in parallel with monotherapies in Phase 2",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:05.599606+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 42,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "a845d93c-4636-4067-b07e-eeb8f07c9ced",
          "evidence": "The slide uses a timeline-based process flow to represent clinical trial phases.",
          "framework": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-05-02 11:32:36.847+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 42,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 43,
      "type": "resolution",
      "title": "The slide uses a visual representation of a bispecific or combination antibody structure.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 60,
        "componentCount": 6,
        "textChars": 512,
        "nDataPoints": 0,
        "notes": "The slide uses a visual representation of a bispecific or combination antibody structure.",
        "elementsJson": null,
        "confidence": 0.95,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.562+00",
          "seconds": 2.852,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/43",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-43",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.2,
            "w": 0.3,
            "x": 0.67,
            "y": 0.23
          },
          "kind": "callout",
          "text": "Ideal building blocks: Spyre's best-in-class engineered mAbs provide optionality for multiple rational combinations",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "16b1c02b-dc21-4c9f-840c-404beb4e10d3",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.3,
            "x": 0.5,
            "y": 0.47
          },
          "kind": "callout",
          "text": "Rapid proof of concept: Parallel progression of portfolio of mAbs will allow evaluation of combinations in Phase 2 studies",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "b0580175-6238-454b-ba94-e1d5c57f80a7",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.2,
            "w": 0.3,
            "x": 0.35,
            "y": 0.23
          },
          "kind": "callout",
          "text": "Established combination precedent: JNJ VEGA study demonstrated unprecedented efficacy despite sub-optimal combination components",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c2bb2097-fa64-4b21-bdb9-4b93e48d6338",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.3,
            "x": 0.02,
            "y": 0.24
          },
          "kind": "image",
          "text": "Antibody structure diagram",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Illustration",
              "slug": "illustration",
              "status": "active",
              "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "illustration",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5c8bbb02-c926-4ccc-8cd8-fdbec61e9e45",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.12,
            "y": 0.7
          },
          "kind": "paragraph",
          "text": "SPY130 SPY120 SPY230",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1f7789d8-0908-4e32-b40e-53c9038c6370",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.03,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre is developing potentially best-in-class combinations to maximize efficacy for patients with IBD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "bd299c7e-d890-48e5-9f45-a535afc1435b",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "2x2 matrix",
            "slug": "matrix-2x2",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
            "version": 1,
            "bodyDocId": null,
            "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "c6e5c85d-d07e-4799-8a01-87b27ee38722",
          "evidence": "Ideal building blocks: Spyre's best-in-class engineered mAbs provide optionality for multiple rational combinations",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:05.680057+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 43,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "60c41f30-ded0-4f7b-a96a-b1be3fd2fa6e",
          "evidence": "JNJ VEGA study cited as precedent",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 43,
          "frameworkName": "authority-citation"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 44,
      "type": "resolution",
      "title": "The slide uses a Venn diagram to show target overlap and a hierarchical tree diagram to show diagnostic-driven treatment selection.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 47,
        "componentCount": 5,
        "textChars": 401,
        "nDataPoints": 0,
        "notes": "The slide uses a Venn diagram to show target overlap and a hierarchical tree diagram to show diagnostic-driven treatment selection.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.812+00",
          "seconds": 3.051,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/44",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-44",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.6,
            "w": 0.33,
            "x": 0.64,
            "y": 0.27
          },
          "kind": "diagram",
          "text": "Precision immunology diagnostic-driven treatment selection tree",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Org chart",
              "slug": "org-chart",
              "status": "active",
              "canonId": "019de52d-04b3-709a-9328-bbcb1643bbc1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "org-chart",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8ffa8ef6-6295-43bd-a1a2-760b92cd6522",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.5,
            "w": 0.25,
            "x": 0.03,
            "y": 0.18
          },
          "kind": "diagram",
          "text": "IBD patients cycle though multiple biologics with modest remission rates",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Process flow",
              "slug": "process",
              "status": "active",
              "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "process",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "408028ef-430a-4768-b644-b41a21a3b043",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.35,
            "w": 0.25,
            "x": 0.35,
            "y": 0.35
          },
          "kind": "diagram",
          "text": "Venn diagram of IL-23, TL1A, and alpha4beta7 targets",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Venn diagram",
              "slug": "venn",
              "status": "active",
              "canonId": "019de52d-0463-710d-b529-cce18d828d2f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "venn",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6f1c0e26-6878-4142-8945-9fd7f5d503a3",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.65,
            "x": 0.29,
            "y": 0.19
          },
          "kind": "title",
          "text": "We believe the future of IBD includes combination therapies and precision approaches to break the therapeutic ceiling",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Action title",
              "slug": "action-title",
              "status": "active",
              "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "action-title",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e928b1c7-cc66-4541-aa00-97cbcad97341",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "We aim to develop companion diagnostics to augment our therapeutic combinations and monotherapies",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6bea620f-47b4-4386-8330-c937aaff3c4d",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Venn diagram",
            "slug": "venn-diagram",
            "status": "active",
            "bestFor": null,
            "canonId": "019de52d-1f53-7290-96c8-79388c95fc17",
            "version": 1,
            "bodyDocId": null,
            "description": null,
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "e3b61ccf-1968-4882-9ad6-1419ffba529d",
          "evidence": "Venn diagram of IL-23, TL1A, and alpha4beta7 targets",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 03:39:05.759463+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 44,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "9146835f-1935-4594-b994-d284da26b00a",
          "evidence": "Diagnostic-led therapeutic selection",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:36.812+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 44,
          "frameworkName": "precision-medicine-framework"
        }
      ],
      "arcBeats": [
        {
          "to": 44,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 10,
          "name": "Solution (Provide relief)",
          "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Solution (Provide relief)",
            "slug": "problem-agitate-solution-solution-provide-relief",
            "status": "active",
            "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd",
            "version": 1,
            "description": null
          },
          "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
          "position": 2,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 45,
      "type": "evidence",
      "title": "The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.",
      "function": "show_traction",
      "rawType": "traction",
      "block": null,
      "metadata": {
        "slideType": "traction",
        "slideTypeCanon": {
          "name": "Traction",
          "slug": "traction",
          "status": "active",
          "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542",
          "version": 1,
          "description": null
        },
        "function": "show_traction",
        "functionCanon": {
          "name": "Show traction",
          "slug": "show_traction",
          "status": "active",
          "canonId": "019de52d-16a8-756a-9b38-a7d35420561d",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 50,
        "componentCount": 5,
        "textChars": 332,
        "nDataPoints": 4,
        "notes": "The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.901+00",
          "seconds": 3.13,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/45",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-45",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.08,
            "w": 0.9,
            "x": 0.05,
            "y": 0.8
          },
          "kind": "callout",
          "text": "Spyre aims to develop genetic companion diagnostics across a portfolio of best-in-class therapeutics",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "09d5f2d9-46eb-4356-a0d1-e6231bfe95d2",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.38,
            "x": 0.12,
            "y": 0.2
          },
          "kind": "chart",
          "text": "Prometheus Biosciences PRA023 TL1A clinical remission at 12 weeks",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Grouped bar chart",
              "slug": "bar-grouped",
              "status": "active",
              "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-grouped",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3a3a5433-d77c-4197-bd6e-f9477f4e5e1e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.38,
            "x": 0.54,
            "y": 0.2
          },
          "kind": "chart",
          "text": "Roivant RVT-3101 TL1A clinical remission at 12 weeks",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Grouped bar chart",
              "slug": "bar-grouped",
              "status": "active",
              "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-grouped",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "de914dd3-7c7c-49c3-9f96-260cee1c1561",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.15,
            "x": 0.02,
            "y": 0.89
          },
          "kind": "source-note",
          "text": "Source: Company materials",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0d420182-dc51-4b7a-865c-fa584d882edb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.8,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Prometheus and Roivant demonstrated POC that a genetic CDx can identify responders to TL1A",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "04e370d1-1351-4fdc-9fa9-a9b3df1b975d",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Chart Selection Guide",
            "slug": "chart-selection-guide",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae",
            "version": 1,
            "bodyDocId": null,
            "description": "Choosing the right chart type for your data and message",
            "familyLabel": null,
            "categoryName": "Slide",
            "categorySlug": "slide"
          },
          "agent": "Designer",
          "layer": "slide",
          "agents": [
            "Designer"
          ],
          "matchId": "21303186-6208-4e9f-ac42-832bdb6b2992",
          "evidence": "chart/bar-grouped: Prometheus Biosciences PRA023 TL1A clinical remission at 12 weeks",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:05.839384+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 45,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "1602fe44-ab6b-4f43-ad39-9ec1cfdc5889",
          "evidence": "Side-by-side comparison of two clinical trial results to prove a hypothesis.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:36.901+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 45,
          "frameworkName": "comparison-frame"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 46,
      "type": "setup",
      "function": "transition",
      "rawType": "section_divider",
      "block": null,
      "metadata": {
        "slideType": "section_divider",
        "slideTypeCanon": {
          "name": "Section divider",
          "slug": "section_divider",
          "status": "active",
          "canonId": "019de52d-066a-7402-9554-6ae504999041",
          "version": 1,
          "description": null
        },
        "function": "transition",
        "functionCanon": {
          "name": "Transition",
          "slug": "transition",
          "status": "active",
          "canonId": "019de52d-1365-7149-92aa-66df859e75fd",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 4,
        "componentCount": 2,
        "textChars": 32,
        "nDataPoints": 0,
        "notes": null,
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.199+00",
          "seconds": 2.409,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/46",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-46",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.2,
            "w": 0.25,
            "x": 0.05,
            "y": 0.1
          },
          "kind": "image",
          "text": "Spyre Therapeutics logo",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8d725bf1-92a1-44a8-b4ac-b17ddf51207b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.2,
            "x": 0.4,
            "y": 0.5
          },
          "kind": "title",
          "text": "Corporate",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.199+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "41cab1cf-c273-4e00-b836-00a5997778d0",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Section divider",
            "slug": "section-divider",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7",
            "version": 1,
            "bodyDocId": null,
            "description": "A transitional slide marking the start of a new section.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "3fdd597b-2fd5-401e-b8e5-8ef5dcfa5076",
          "evidence": "Corporate",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-07-17 03:39:05.921554+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 46,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 47,
      "type": "setup",
      "title": "The slide includes a section for Management team and a section for Board of Directors, with headshots and titles for each individual, followed by a logo grid of",
      "function": "other",
      "rawType": "team_bio",
      "block": null,
      "metadata": {
        "slideType": "team_bio",
        "slideTypeCanon": {
          "name": "Team bio",
          "slug": "team_bio",
          "status": "active",
          "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e",
          "version": 1,
          "description": null
        },
        "function": "other",
        "functionCanon": {
          "name": "Other (fallback)",
          "slug": "other",
          "status": "active",
          "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 39,
        "componentCount": 6,
        "textChars": 128,
        "nDataPoints": 0,
        "notes": "The slide includes a section for Management team and a section for Board of Directors, with headshots and titles for each individual, followed by a logo grid of affiliated organizations.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:39.446+00",
          "seconds": 5.54,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/47",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-47",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.615,
            "w": 0.47,
            "x": 0.029,
            "y": 0.258
          },
          "kind": "image",
          "text": "Management team headshots",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "abb3bea8-039b-40aa-a987-faeb3fe788ba",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.615,
            "w": 0.945,
            "x": 0.525,
            "y": 0.258
          },
          "kind": "image",
          "text": "Board of Directors headshots",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f1d86c64-004c-479b-9673-6e2e908a7004",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.085,
            "w": 0.915,
            "x": 0.085,
            "y": 0.72
          },
          "kind": "image",
          "text": "Affiliated company logos",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo grid",
              "slug": "logo-grid",
              "status": "active",
              "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo-grid",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f3510600-a4e3-49bd-ac6b-0e5661ceef48",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.024,
            "w": 0.155,
            "x": 0.148,
            "y": 0.168
          },
          "kind": "title",
          "text": "Management team",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "1f8c6469-cc72-4406-b106-2d3a7a9b2ed9",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.024,
            "w": 0.171,
            "x": 0.637,
            "y": 0.168
          },
          "kind": "title",
          "text": "Board of Directors",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "81769a90-ea61-4703-bd06-5193daad4bd0",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.048,
            "w": 0.235,
            "x": 0.026,
            "y": 0.038
          },
          "kind": "title",
          "text": "Leadership and BOD",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:39.446+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8d55fc87-c818-4360-8056-3c7535de976e",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 48,
      "type": "resolution",
      "title": "The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.",
      "function": "plan_implementation",
      "rawType": "roadmap",
      "block": null,
      "metadata": {
        "slideType": "roadmap",
        "slideTypeCanon": {
          "name": "Roadmap",
          "slug": "roadmap",
          "status": "active",
          "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c",
          "version": 1,
          "description": null
        },
        "function": "plan_implementation",
        "functionCanon": {
          "name": "Plan implementation",
          "slug": "plan_implementation",
          "status": "active",
          "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 26,
        "componentCount": 4,
        "textChars": 177,
        "nDataPoints": 0,
        "notes": "The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.562+00",
          "seconds": 2.498,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/48",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-48",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.65,
            "w": 0.92,
            "x": 0.04,
            "y": 0.16
          },
          "kind": "framework",
          "text": "Timeline of clinical milestones",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Framework",
              "slug": "framework",
              "status": "active",
              "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa",
              "version": 1,
              "description": "Named conceptual framework instance."
            },
            "tool": null,
            "subkind": {
              "name": "Framework instance",
              "slug": "instance",
              "status": "active",
              "canonId": "019de52d-05a2-72af-be0b-7edc60708a03",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "instance",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "da5dd5df-4ae8-4a80-8c1a-d16c95f7851b",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.7,
            "x": 0.15,
            "y": 0.84
          },
          "kind": "paragraph",
          "text": "$200M expected to fund broad pipeline into 2026 through multiple key value creation events",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "79b5c086-f37b-4458-b3a6-3d2d87686793",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.65,
            "w": 0.92,
            "x": 0.04,
            "y": 0.16
          },
          "kind": "table",
          "text": "Pipeline milestones table",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9e439b7c-4010-4dec-8af0-af23d555d081",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.06,
            "w": 0.4,
            "x": 0.02,
            "y": 0.03
          },
          "kind": "title",
          "text": "Cash and anticipated milestones",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3289275c-1a88-4e1b-8a0e-a6fe9d5cb03c",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [
        {
          "matchId": "4ff8b655-97ad-4bbd-88f3-c02fff3cf7de",
          "evidence": "The slide maps specific project milestones against a chronological timeline (2023-2025).",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 48,
          "frameworkName": "gantt-chart"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 49,
      "type": "setup",
      "title": "The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).",
      "function": "compare_peers",
      "rawType": "peer_benchmark",
      "block": null,
      "metadata": {
        "slideType": "peer_benchmark",
        "slideTypeCanon": {
          "name": "Peer benchmark",
          "slug": "peer_benchmark",
          "status": "active",
          "canonId": "019de52d-08f0-7158-a78d-d7b5331fefaf",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 57,
        "componentCount": 5,
        "textChars": 413,
        "nDataPoints": 20,
        "notes": "The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:40.465+00",
          "seconds": 6.336,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/49",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-49",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.06,
            "w": 0.7,
            "x": 0.28,
            "y": 0.87
          },
          "kind": "callout",
          "text": "Initial financing rounds expected to generate valuable milestones.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "483d640b-f512-41bd-9df8-2db54cd30752",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.45,
            "w": 0.18,
            "x": 0.24,
            "y": 0.25
          },
          "kind": "chart",
          "text": "Market cap range visualization (Min, IPO, Today, Max)",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Horizontal bar chart",
              "slug": "bar-horizontal",
              "status": "active",
              "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-horizontal",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "54593fdd-e6e5-41d9-bb31-41d5abd0a38e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.25,
            "x": 0.02,
            "y": 0.87
          },
          "kind": "source-note",
          "text": "NOTE: “Today” market cap as of April 17, 2023 SOURCE: FactSet. Company S-1s.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5241be3b-64b7-48dd-8c51-f239426f3729",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.68,
            "w": 0.96,
            "x": 0.02,
            "y": 0.188
          },
          "kind": "table",
          "text": "Table comparing Prometheus, Morphic, Dice, Ventyx, Pliant, and Spyre across IPO raise, market cap, clinical stage, and program status.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "4eec8970-938f-47e9-a06f-354d2bddb75f",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "I&I companies with compelling science have maintained value even in market downturns",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "cbb02862-1d7c-4a91-86d5-557c7dba46cc",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Table data",
            "slug": "table-data",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
            "version": 1,
            "bodyDocId": null,
            "description": "Tabular layouts of structured data.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "4d3ad0d8-1f90-4f7a-80f0-21d702b51bb9",
          "evidence": "Table comparing Prometheus, Morphic, Dice, Ventyx, Pliant, and Spyre across IPO raise, market cap, clinical stage, and program status.",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:06.085746+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 49,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "f1f8b13a-924e-48e2-812e-ac3a52d0c0e1",
          "evidence": "Compares peer company performance metrics against internal projections.",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:40.465+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 49,
          "frameworkName": "comparison-frame"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 50,
      "type": "setup",
      "title": "The table maps historical M&A deal values to Spyre's internal pipeline milestones.",
      "function": "compare_peers",
      "rawType": "comparison_table",
      "block": null,
      "metadata": {
        "slideType": "comparison_table",
        "slideTypeCanon": {
          "name": "Comparison table",
          "slug": "comparison_table",
          "status": "active",
          "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2",
          "version": 1,
          "description": null
        },
        "function": "compare_peers",
        "functionCanon": {
          "name": "Compare peers",
          "slug": "compare_peers",
          "status": "active",
          "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 41,
        "componentCount": 4,
        "textChars": 282,
        "nDataPoints": 12,
        "notes": "The table maps historical M&A deal values to Spyre's internal pipeline milestones.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.562+00",
          "seconds": 2.403,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/50",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-50",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.05,
            "w": 0.62,
            "x": 0.02,
            "y": 0.85
          },
          "kind": "callout",
          "text": "Comparable acquisitions illustrate optionality that exists for potential exits.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "7354a6f4-e7ce-4fa8-a3e9-df2c4c15b96e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.02,
            "w": 0.15,
            "x": 0.02,
            "y": 0.91
          },
          "kind": "source-note",
          "text": "SOURCE: Press releases.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "afcf28c3-f86c-4165-bc9a-09e48bd9aaf7",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.68,
            "w": 0.96,
            "x": 0.02,
            "y": 0.18
          },
          "kind": "table",
          "text": "Acquirer, Target, Deal economics, Status, Spyre timeline",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Table",
              "slug": "table",
              "status": "active",
              "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28",
              "version": 1,
              "description": "Tabular data layout."
            },
            "tool": null,
            "subkind": {
              "name": "Data table",
              "slug": "data",
              "status": "active",
              "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "data",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "9dd52dc1-c81a-4dff-8f3d-04ab72380377",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Acquisitions illustrate value of validated targets in I&I, which have supported multiple transactions >$1B per Spyre program",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "f796b8ca-7018-4770-beaa-0cba1a80bd79",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Table data",
            "slug": "table-data",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d",
            "version": 1,
            "bodyDocId": null,
            "description": "Tabular layouts of structured data.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "53980d8d-7a79-4d1f-a817-6be83f6bdbe1",
          "evidence": "table/data: Acquirer, Target, Deal economics, Status, Spyre timeline",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 03:39:06.165645+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 50,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "ef682ad4-ffe5-4c41-bae0-ab5f6d49d0ac",
          "evidence": "Table comparing external M&A benchmarks to internal pipeline milestones",
          "framework": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-05-02 11:32:36.562+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 50,
          "frameworkName": "comparison_frame"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 51,
      "type": "setup",
      "function": "state_next_steps",
      "rawType": "closing_ask",
      "block": null,
      "metadata": {
        "slideType": "closing_ask",
        "slideTypeCanon": {
          "name": "Closing ask",
          "slug": "closing_ask",
          "status": "active",
          "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c",
          "version": 1,
          "description": null
        },
        "function": "state_next_steps",
        "functionCanon": {
          "name": "State next steps",
          "slug": "state_next_steps",
          "status": "active",
          "canonId": "019de52d-14ca-70ac-b534-971f458cdf29",
          "version": 1,
          "description": null
        },
        "density": "sparse",
        "densityScore": 1,
        "componentCount": 1,
        "textChars": 9,
        "nDataPoints": 0,
        "notes": null,
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:36.972+00",
          "seconds": 2.743,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/51",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-51",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.067,
            "w": 0.215,
            "x": 0.125,
            "y": 0.533
          },
          "kind": "title",
          "text": "Thank you",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:36.972+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "443c5a6c-3a99-4ef5-be09-6f424f24b7dd",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Storytelling: the closing ask",
            "slug": "closing-ask",
            "status": "active",
            "bestFor": null,
            "canonId": "019df269-24e0-70ab-8dd9-983832c1c665",
            "version": 1,
            "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d",
            "description": "The single most important slide in the deck — after the cover. The final",
            "familyLabel": "narrative-block",
            "categoryName": "Narrative & Transformation",
            "categorySlug": "narrative-transformation"
          },
          "agent": "storyteller",
          "layer": "slide",
          "agents": [
            "storyteller"
          ],
          "matchId": "b0756db2-7914-450b-83b3-e36e3e06e7c4",
          "evidence": "Thank you",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.9,
          "extraction": {
            "at": "2026-07-17 03:39:06.246653+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 51,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 52,
      "type": "setup",
      "title": "The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apog",
      "function": "other",
      "rawType": "team_bio",
      "block": null,
      "metadata": {
        "slideType": "team_bio",
        "slideTypeCanon": {
          "name": "Team bio",
          "slug": "team_bio",
          "status": "active",
          "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e",
          "version": 1,
          "description": null
        },
        "function": "other",
        "functionCanon": {
          "name": "Other (fallback)",
          "slug": "other",
          "status": "active",
          "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce",
          "version": 1,
          "description": null
        },
        "density": "overcrowded",
        "densityScore": 85,
        "componentCount": 9,
        "textChars": 696,
        "nDataPoints": 4,
        "notes": "The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogee Therapeutics.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.773+00",
          "seconds": 3.378,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/52",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-52",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.9,
            "y": 0.565
          },
          "kind": "image",
          "text": "Neta Batscha, VP Operations & Strategy",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5475c441-40e9-4187-9dda-cd29073182a6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.615,
            "y": 0.565
          },
          "kind": "image",
          "text": "Shawn Russell, VP CMC",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "65ca73b6-63b5-40a1-8c20-81580b40ecd0",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.615,
            "y": 0.345
          },
          "kind": "image",
          "text": "Evan Thompson, COO",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "826187c5-973a-4f6c-a470-e81dbadeb8bd",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.76,
            "y": 0.565
          },
          "kind": "image",
          "text": "Cyrus Stacey, VP Quality",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ce40a1db-3de0-4253-97c3-9364d3556ed6",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.76,
            "y": 0.345
          },
          "kind": "image",
          "text": "Hussam Shaheen, SVP Biotherapeutics",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d8b588ab-2465-4244-977f-07c5e8253afe",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.9,
            "y": 0.345
          },
          "kind": "image",
          "text": "Jason Oh, VP Biology",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Headshot",
              "slug": "headshot",
              "status": "active",
              "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headshot",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e0907cff-09cb-4388-969d-c3f61e4a7c29",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.09,
            "w": 0.265,
            "x": 0.695,
            "y": 0.215
          },
          "kind": "image",
          "text": "Paragon Therapeutics logo",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Logo",
              "slug": "logo",
              "status": "active",
              "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "logo",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "92c90362-0e6d-41ba-8b48-4be89ad972dd",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.5,
            "x": 0.025,
            "y": 0.195
          },
          "kind": "list",
          "text": "was founded in 2021 by Fairmount. 21 Professionals with deep expertise in antibody engineering and drug development from across the industry. by facilities and scientists at FairJourney Biologics and contract research organizations across the globe. 12 Programs currently in development with lead program on track to enter clinical trials in 3Q23, less than 2 years from ideation. Apogee Therapeutics, in 2022, which went public in July 2023 in a $345M IPO.",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a26b093a-706e-4ce3-807d-e01a4cb36ce4",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.12,
            "w": 0.75,
            "x": 0.025,
            "y": 0.04
          },
          "kind": "title",
          "text": "Spyre antibodies were developed by our partners at Paragon",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.773+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ecfd93c8-3669-4730-abc2-b917065398aa",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 53,
      "type": "setup",
      "title": "The slide uses a series of icons to represent different scientific methodologies.",
      "function": "present_solution",
      "rawType": "unfair_advantage",
      "block": null,
      "metadata": {
        "slideType": "unfair_advantage",
        "slideTypeCanon": {
          "name": "Unfair advantage",
          "slug": "unfair_advantage",
          "status": "active",
          "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 51,
        "componentCount": 5,
        "textChars": 478,
        "nDataPoints": 0,
        "notes": "The slide uses a series of icons to represent different scientific methodologies.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.873+00",
          "seconds": 3.117,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/53",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-53",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.12,
            "w": 0.8,
            "x": 0.1,
            "y": 0.69
          },
          "kind": "callout",
          "text": "Established workflows and CRO relationships enable fast and reliable antibody discovery to generate novel drug candidates with best-in-class properties",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8f153d56-8690-4a65-bdae-68b6da6a8965",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.25,
            "w": 0.84,
            "x": 0.08,
            "y": 0.33
          },
          "kind": "image",
          "text": null,
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Image",
              "slug": "image",
              "status": "active",
              "canonId": "019de52c-f978-701f-a720-51d029d769e7",
              "version": 1,
              "description": "Photo, illustration, screenshot or icon."
            },
            "tool": null,
            "subkind": {
              "name": "Icon grid",
              "slug": "icon-grid",
              "status": "active",
              "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "icon-grid",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e2d4b030-41f7-40fe-a053-a2a1291e6f7d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.84,
            "x": 0.08,
            "y": 0.52
          },
          "kind": "list",
          "text": "Cross-species immunization, Hybridoma approaches, Single B-cell cloning, Phage display, Yeast display, In-silico design",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "3528c3b6-2559-49bd-adfc-df196bb7db96",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.95,
            "x": 0.03,
            "y": 0.24
          },
          "kind": "paragraph",
          "text": "Antibody engineering expertise in a variety of techniques to fulfill the needs of a wide range of programs",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4",
              "version": 1,
              "description": "Single prose block in the body of a slide."
            },
            "tool": null,
            "subkind": {
              "name": "Paragraph",
              "slug": "paragraph",
              "status": "active",
              "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "paragraph",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "6ef4ce45-76a1-4121-81b5-abefde494094",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.85,
            "x": 0.02,
            "y": 0.04
          },
          "kind": "title",
          "text": "Diverse expertise in antibody discovery and engineering enables potentially best-in-class therapeutics",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.873+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c0625154-3c0a-49c0-8960-3cf334ee5f39",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "List presentation",
            "slug": "list-presentation",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1",
            "version": 1,
            "bodyDocId": null,
            "description": "Bulleted, numbered, or checklist enumerations.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "39871475-b15f-4f64-accc-efc99bc20edc",
          "evidence": "list/bullet: Cross-species immunization, Hybridoma approaches, Single B-cell cloning, Phage display, Yeast display, In-silico design",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-07-17 00:31:50.268198+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 53,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 54,
      "type": "resolution",
      "title": "The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 40,
        "componentCount": 4,
        "textChars": 428,
        "nDataPoints": 0,
        "notes": "The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:38.698+00",
          "seconds": 3.579,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/54",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-54",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.1,
            "w": 0.1,
            "x": 0.545,
            "y": 0.15
          },
          "kind": "chart",
          "text": "Potency curve",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Line chart",
              "slug": "line",
              "status": "active",
              "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "line",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.698+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "2bca150a-15ae-4d41-bdb6-be6adc373074",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.7,
            "w": 0.5,
            "x": 0.25,
            "y": 0.2
          },
          "kind": "framework",
          "text": "Five-pillar optimization framework",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Framework",
              "slug": "framework",
              "status": "active",
              "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa",
              "version": 1,
              "description": "Named conceptual framework instance."
            },
            "tool": null,
            "subkind": {
              "name": "Framework instance",
              "slug": "instance",
              "status": "active",
              "canonId": "019de52d-05a2-72af-be0b-7edc60708a03",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "instance",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.698+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "d33a718e-1dc6-4179-8e2b-be277391408d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.7,
            "w": 0.9,
            "x": 0.05,
            "y": 0.2
          },
          "kind": "list",
          "text": "1. Potency: Targeting the best epitope and maximizing in vitro responses\n2. Safety: Target specificity and low immunogenicity\n3. Manufacturability: Plug-and-play manufacturing and highly stable\n4. Formulatability: More drug and less pain\n5. Pharmacokinetics: Longer half-life for fewer shots",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.698+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e5a02288-64b5-4004-98d4-d9f107b869ae",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.02,
            "y": 0.03
          },
          "kind": "title",
          "text": "Paragon aims to engineer best-in-class antibodies by optimizing across five key properties",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.698+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c3b2f05a-ee7b-4ff5-83af-2d184dca6376",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "2x2 matrix",
            "slug": "matrix-2x2",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8",
            "version": 1,
            "bodyDocId": null,
            "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.",
            "familyLabel": null,
            "categoryName": null,
            "categorySlug": null
          },
          "agent": null,
          "layer": "slide",
          "agents": null,
          "matchId": "210e15bc-7c58-4967-b2b4-3521e5fb8f10",
          "evidence": "framework/instance: Five-pillar optimization framework",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.5,
          "extraction": {
            "at": "2026-07-17 00:31:50.343277+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 54,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": "common",
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "9bcf1a98-ab22-448c-9963-864f73bc4a51",
          "evidence": "Visual pentagon structure used to categorize five distinct engineering properties.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:38.698+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 54,
          "frameworkName": "pentagon-optimization-model"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 55,
      "type": "resolution",
      "title": "The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.",
      "function": "present_solution",
      "rawType": "solution",
      "block": null,
      "metadata": {
        "slideType": "solution",
        "slideTypeCanon": {
          "name": "Solution",
          "slug": "solution",
          "status": "active",
          "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282",
          "version": 1,
          "description": null
        },
        "function": "present_solution",
        "functionCanon": {
          "name": "Present solution",
          "slug": "present_solution",
          "status": "active",
          "canonId": "019de52d-15b8-71da-bd23-2b767850cbce",
          "version": 1,
          "description": null
        },
        "density": "balanced",
        "densityScore": 38,
        "componentCount": 4,
        "textChars": 385,
        "nDataPoints": 0,
        "notes": "The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:38.37+00",
          "seconds": 3.244,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/55",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-55",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.7,
            "w": 0.63,
            "x": 0.02,
            "y": 0.2
          },
          "kind": "diagram",
          "text": "Comparison of 1st gen mAb vs Spyre mAb recycling pathways via FcRn",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Diagram",
              "slug": "diagram",
              "status": "active",
              "canonId": "019de52c-f9f0-734a-81de-15382ff28c65",
              "version": 1,
              "description": "Schematic or relational diagram."
            },
            "tool": null,
            "subkind": {
              "name": "Process flow",
              "slug": "process",
              "status": "active",
              "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "process",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.37+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "c4b7ab0c-5f0b-4d03-943a-156052b72827",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.3,
            "w": 0.3,
            "x": 0.67,
            "y": 0.35
          },
          "kind": "list",
          "text": "Spyre mAbs designed to be recycled back into circulation more readily; Drug exists at much higher levels for longer duration of effect; Fewer injections decrease patient burden and can improve compliance and penetration",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "List",
              "slug": "list",
              "status": "active",
              "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2",
              "version": 1,
              "description": "Bullet or numbered list."
            },
            "tool": null,
            "subkind": {
              "name": "Bullet list",
              "slug": "bullet",
              "status": "active",
              "canonId": "019de52c-fc98-7169-a083-5cab805076ca",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bullet",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.37+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "0706dc15-9d07-4b5e-b647-5f0f9a0a5332",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.03,
            "w": 0.2,
            "x": 0.02,
            "y": 0.95
          },
          "kind": "source-note",
          "text": "SOURCE: Adapted from Ko S et al BioDrugs 2021",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.37+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "8fa518ed-3030-4e5b-92f9-cee6027a5d0a",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.08,
            "w": 0.85,
            "x": 0.02,
            "y": 0.03
          },
          "kind": "title",
          "text": "Spyre mAbs employ proven half-life extension technology",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:38.37+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "a29b739d-8e2c-4f2d-be46-fcdb60670a0e",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Before-After-Bridge",
            "slug": "before-after-bridge",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-8604-7188-883f-42370288ad05",
            "version": 1,
            "bodyDocId": null,
            "description": "Narrative structure: Paint the before, show the after, explain the bridge",
            "familyLabel": null,
            "categoryName": "Block",
            "categorySlug": "block"
          },
          "agent": "Storyteller",
          "layer": "slide",
          "agents": [
            "Storyteller"
          ],
          "matchId": "ad59d031-a01e-4d24-b04f-e7b9543b9617",
          "evidence": "diagram/process: Comparison of 1st gen mAb vs Spyre mAb recycling pathways via FcRn",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.7,
          "extraction": {
            "at": "2026-07-17 00:31:50.417956+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 55,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [
        {
          "matchId": "60cfd52e-2ba2-4706-a3d0-78bcb57af41b",
          "evidence": "The diagram illustrates the biological process of antibody recycling.",
          "framework": null,
          "confidence": 0.8,
          "extraction": {
            "at": "2026-05-02 11:32:38.37+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 55,
          "frameworkName": "process"
        }
      ],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    },
    {
      "page": 56,
      "type": "evidence",
      "title": "The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.",
      "function": "show_traction",
      "rawType": "traction",
      "block": null,
      "metadata": {
        "slideType": "traction",
        "slideTypeCanon": {
          "name": "Traction",
          "slug": "traction",
          "status": "active",
          "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542",
          "version": 1,
          "description": null
        },
        "function": "show_traction",
        "functionCanon": {
          "name": "Show traction",
          "slug": "show_traction",
          "status": "active",
          "canonId": "019de52d-16a8-756a-9b38-a7d35420561d",
          "version": 1,
          "description": null
        },
        "density": "dense",
        "densityScore": 53,
        "componentCount": 5,
        "textChars": 351,
        "nDataPoints": 10,
        "notes": "The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.",
        "elementsJson": null,
        "confidence": 1,
        "extraction": {
          "model": "google/gemini-3.1-flash-lite-preview-20260303",
          "runId": null,
          "at": "2026-05-02 11:32:37.781+00",
          "seconds": 2.581,
          "promptVersion": "v2-canon-conditioned"
        }
      },
      "links": {
        "slide": "/slides/019de075-d132-769f-97bd-4a840dd24899/56",
        "deck": "/decks/019de075-d132-769f-97bd-4a840dd24899",
        "deckAnchor": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-56",
        "deckJson": "/decks/019de075-d132-769f-97bd-4a840dd24899.json"
      },
      "components": [
        {
          "bbox": {
            "h": 0.07,
            "w": 0.38,
            "x": 0.08,
            "y": 0.8
          },
          "kind": "callout",
          "text": "Extent of half-life extension dependent on target (soluble vs. membrane bound)",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Callout",
              "slug": "callout",
              "status": "active",
              "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2",
              "version": 1,
              "description": "Highlighted callout box."
            },
            "tool": null,
            "subkind": {
              "name": "Primary callout",
              "slug": "primary",
              "status": "active",
              "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "primary",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.781+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "ac8a576d-0a63-4018-9469-205f7fa977bc",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.6,
            "w": 0.4,
            "x": 0.55,
            "y": 0.25
          },
          "kind": "chart",
          "text": "ADA rates are similar for YTE and non-YTE antibodies",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Grouped bar chart",
              "slug": "bar-grouped",
              "status": "active",
              "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "bar-grouped",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.781+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "e0c98ab3-cea1-4e05-a352-37480702bedb",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.55,
            "w": 0.45,
            "x": 0.05,
            "y": 0.25
          },
          "kind": "chart",
          "text": "YTE mAbs have extended half-lives in NHPs and humans",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Chart",
              "slug": "chart",
              "status": "active",
              "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8",
              "version": 1,
              "description": "Quantitative chart."
            },
            "tool": null,
            "subkind": {
              "name": "Scatter plot",
              "slug": "scatter",
              "status": "active",
              "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "scatter",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.781+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "033fb865-1d6c-4f15-a2bd-cabb63cf3b8e",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.05,
            "w": 0.4,
            "x": 0.05,
            "y": 0.88
          },
          "kind": "source-note",
          "text": "Source: 1) Rocca, A, et al. Int J of Mol Sci, 2021; 2) Domachowske NEJM 2022",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Source note",
              "slug": "source-note",
              "status": "active",
              "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948",
              "version": 1,
              "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered."
            },
            "tool": null,
            "subkind": null,
            "framework": null
          },
          "subkind": null,
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.781+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "062d484d-89b3-42f5-87cb-c1dd9c2a737d",
          "parentComponentId": null
        },
        {
          "bbox": {
            "h": 0.15,
            "w": 0.8,
            "x": 0.05,
            "y": 0.05
          },
          "kind": "title",
          "text": "YTE technology shown to significantly prolong half-life and without increasing immunogenicity",
          "attrs": null,
          "canon": {
            "kind": {
              "name": "Title",
              "slug": "title",
              "status": "active",
              "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4",
              "version": 1,
              "description": "Slide title or headline."
            },
            "tool": null,
            "subkind": {
              "name": "Headline",
              "slug": "headline",
              "status": "active",
              "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d",
              "version": 1,
              "description": null
            },
            "framework": null
          },
          "subkind": "headline",
          "groupRole": null,
          "confidence": null,
          "extraction": {
            "at": "2026-05-02 11:32:37.781+00",
            "model": "google/gemini-3.1-flash-lite-preview-20260303",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "componentId": "5970917b-92e0-4e46-adf9-7b95ff539c64",
          "parentComponentId": null
        }
      ],
      "metrics": [],
      "tools": [
        {
          "tool": {
            "name": "Chart Selection Guide",
            "slug": "chart-selection-guide",
            "status": "active",
            "bestFor": null,
            "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae",
            "version": 1,
            "bodyDocId": null,
            "description": "Choosing the right chart type for your data and message",
            "familyLabel": null,
            "categoryName": "Slide",
            "categorySlug": "slide"
          },
          "agent": "Designer",
          "layer": "slide",
          "agents": [
            "Designer"
          ],
          "matchId": "b585621c-2456-4f5b-8a0f-e9ddb9086eb0",
          "evidence": "chart/scatter: YTE mAbs have extended half-lives in NHPs and humans chart/bar-grouped: ADA rates are similar for YTE and non-YTE antibodies",
          "pageRefs": null,
          "priority": null,
          "whenToUse": null,
          "confidence": 0.6,
          "extraction": {
            "at": "2026-07-17 00:31:50.492834+00",
            "model": "or:meta-llama/llama-4-scout",
            "runId": null,
            "seconds": null,
            "promptVersion": null
          },
          "pageNumber": 56,
          "whyItWorks": null,
          "antipattern": null,
          "cardinality": null,
          "narrativePurpose": null
        }
      ],
      "frameworks": [],
      "arcBeats": [
        {
          "to": 56,
          "arc": {
            "name": "Problem-Agitate-Solution",
            "slug": "problem-agitate-solution",
            "status": "active",
            "bestFor": "Sales pitches, urgency-driven, competitive displacement",
            "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf",
            "version": 1,
            "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49",
            "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)",
            "description": null,
            "familyLabel": null
          },
          "from": 45,
          "name": "Impact & Next Steps",
          "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
          "matchId": "6ca3fc7b-1fa7-49dc-aa08-59252f7311e5",
          "beatType": {
            "name": "Impact & Next Steps",
            "slug": "consultants-gambit-impact-next-steps",
            "status": "active",
            "canonId": "019dd9b8-0849-7728-9ee9-fd1609c4c655",
            "version": 1,
            "description": null
          },
          "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
          "position": 3,
          "isPrimaryArc": true,
          "parentBeatType": {
            "name": "Resolution",
            "slug": "resolution",
            "status": "active",
            "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b",
            "version": 1,
            "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution."
          },
          "alignedBlockIds": null,
          "matchConfidence": 0.8
        }
      ],
      "loops": [],
      "locked": true
    }
  ],
  "arcBeats": [
    {
      "from": 8,
      "to": 8,
      "label": "Problem (Identify pain)",
      "description": "The document identifies the limitations of current biologics and the need for new approaches."
    },
    {
      "from": 8,
      "to": 15,
      "label": "Agitate (Make it worse)",
      "description": "The document highlights the growing market and the need for improved solutions, emphasizing the limitations of current treatments."
    },
    {
      "from": 10,
      "to": 44,
      "label": "Solution (Provide relief)",
      "description": "The document presents Spyre's pipeline and solution for IBD treatment."
    },
    {
      "from": 45,
      "to": 56,
      "label": "Impact & Next Steps",
      "description": "The document outlines the potential impact and next steps for Spyre's pipeline."
    }
  ],
  "loops": [
    {
      "from": 10,
      "to": 19,
      "label": "Aha Moment",
      "description": "What if Spyre's mAbs could provide a best-in-class solution for IBD treatment?"
    },
    {
      "from": 11,
      "to": 11,
      "label": "Why Now",
      "description": "Why now is the right time for Spyre's IBD treatment solutions?"
    },
    {
      "from": 28,
      "to": 28,
      "label": "Quick Win Big Bet",
      "description": "What if Spyre's combination programs could create optimal combinations in IBD?"
    }
  ]
}